Medical and Pharmaceutical Biotechnology master degree programme

Looking for an internationally respected master programme that will open up exciting career opportunities in the pharmaceutical industry and research? Potential employers hold our Medical and Pharmaceutical Biotechnology programme in high regard thanks to its broad curriculum.

On the master programme, you enhance your methods-based and problem-solving competencies, putting you in a position to overcome the challenges associated with developing and producing innovative treatments for cancer, autoimmune conditions and neurodegenerative diseases. You use cutting-edge and interdisciplinary methods, such as culturing “mini tumours” to help predict the effects of cancer treatments.

The degree programme

Our four-semester, English-language Medical and Pharmaceutical Biotechnology master degree programme is designed to provide you with extensive medical biotechnology knowledge and expertise in biotech product development and manufacturing. It is very well embedded in the Vienna Biotech Region.

Developing an interdisciplinary mindset

An interdisciplinary approach is the key to success in biotechnology. To this end, you build on your knowledge of natural sciences, medical and engineering aspects.

Developing high-level expertise in identifying, characterising and manufacturing biopharmaceuticals is an essential aspect of this master programme. Manufacturing biopharmaceuticals also requires extensive knowledge of the applicable legal framework and the quality assurance procedures which play a vital part in an interdisciplinary setting.

Focusing on the needs of the industry

A team of about 40 lecturers from research and industry teach basic and applied topics and how to take advanced therapies from research to application. Paired with plenty of lab work, this ensures that the programme has a strong practical focus and is aligned with the requirements of industry.

The curriculum also features current trends and the latest developments: for instance, you use cutting-edge technologies, such as shotgun proteomics, to carry out a computerised bioinformatic analysis of all of a cell’s proteins under normal and pathological conditions. The programme also offers complementary training in development, application and production methods for quality-assured tissue and organ replacements.

International by heart

Interested in joint classes with students from other universities? Within an ERASMUS Plus Project, a joint module covering the main aspects of drug development is being developed. For the project, our university is collaborating with the French Université Paris XII Val De Marne (UPEC) and Finnish Turku University of Applied Sciences (TUAS).

The programme covers the research focuses of each partner institution. The theory courses will be held as interactive courses in the virtual classroom in autumn, whereas the laboratory courses will take place on site at the partner institutions in spring.

A particularly attractive option is the dual degree we offer in conjunction with the Linköping University in Sweden. Besides obtaining a master of science at IMC Krems, you will also be accredited with completing the Experimental and Medical Biosciences programme at our partner institution.

Excellent career & PhD opportunities

When you graduate, you can choose from a wide range of career paths – the international nature of the programme opens up opportunities in the domestic and global biotechnology industry or in a variety of PhD programmes.

Here is a short overview of established PhD cooperations:

The Transformation of Pre-Clinics into Clinics by Organoids (TOPICO) project is a novel PhD programme, which is embedded in the Malignant Disease programme of the Medical University of Vienna, but also synergistically extends important contents of the Medical and Pharmaceutical Biotechnology master programme of IMC University of Applied Sciences Krems.
This creates a unique environment for PhD students to develop their individual PhD projects in a well-founded network of students and faculty, thereby promoting their later careers in international cancer research in industrial or academic settings.
A collaboration with the University for Continuing Education in Krems has been in place for several years in the PhD programme Regenerative Medicine. For graduates of the master programme Medical and Pharmaceutical Biotechnology, this is another opportunity to start a PhD in this innovative field.

Studium Medical and Pharmaceutical Biotechnology - Studierende steht hinter einer Glasfront und pipettiert

Studium Medical and Pharmaceutical Biotechnology - 2 Mitarbeiter vor einem Computer

Studium Medical and Pharmaceutical Biotechnology - 2 Studierende stehen im Labor

" After completing your degree, you will be able start building a career in the international biotechnology industry or on a doctoral programme. "
Programme director Harald Hundsberger

A formula for success: theoretical knowledge + practical experience

The programme is built on three pillars.

1
1. Advanced courses
Semesters 1-2
While the Medical and Pharmaceutical Biotechnology bachelor programme has a strong focus on the natural sciences, the emphasis shifts to the methods-based and problem-solving skills required in the field in the master programme.
In the first two semesters, you’ll build on the knowledge you acquired in our bachelor degree or another related programme. Modules include Health, Disease and Therapeutical Strategies, Process Design, Bioprocess Technology and Analytical Methods in Life Sciences. You’ll also start preparing for your research semester in semester 1.
On top of this, the Institute of Biotechnology hosts its annual Life Science Meeting, which is designed to be a very broad-based scientific conference. There’s always an exciting international atmosphere at this event, where you’ll benefit from the insights of globally respected scientists from research and industry. The programme also features presentations by our students and graduates.
2
2. The electives
Semesters 1-4
Right from the first semester, you have the opportunity to tailor your degree according to your specific interests. You select one of two electives: Bioprocess Engineering or Advanced Therapeutics Development.
Both of these will give you an overview of the current research landscape: you will learn about numerous research projects connected to your specialism and the Institute of Biotechnology’s research focuses.
This is a fantastic opportunity to become an expert in your chosen field: the elective you select will help give your professional profile a sharper focus. Ideally, in the next semester you will choose a research topic and internship placement linked to your specialism.
3
3. The research semester and master thesis
Semester 3-4
The research phase is a core element of the master programme. You can start the research work for the master thesis already after the 2nd semester as the lectures of the 3rd and 4th semesters are online lectures and with that spend up to one year at a respected biotechnology company or research facility in Austria or abroad. Examples include the Massachusetts Institute of Technology (MIT) in the United States or Karolinska Institutet in Sweden. The work will focus on a project that forms the basis for your master thesis.
After your research semesters, you only have to return to university to take your final master examination. So, if you’re offered a permanent job or a Ph.D. position by your internship provider, there’ll be nothing standing in your way.

Curriculum

What can you expect from your studies? The curriculum provides an overview.

Click on the individual courses for further information.

Course	SWS	ECTS
Health, Disease and Therapeutical Strategies
Immunology	2	3
Immunology Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: IMM1VO Contact hours per week: 2 ECTS: 3 Course Content: The haematopoietic and lymphoid system Genetic variability in the immune system Antigen recognition by B-cell and T-cell receptors Antigen presenting cells (DCs, macrophages, B-cells), cytokines and chemokines Innate immune response (complement, macrophages, NK cells) Development and classification of lymphocytes Cell-mediated and humoral immune responses Primary immune response and memory cells Resistance, autoimmune disorders and transplants Allergies and hereditary immune deficiencies Viral and bacterial infections Treating protozoan and fungal diseases Immunology research methods Course outcome: Upon completion of this course students are able to: explain the complex physiology of the immune system, summarize the activation of immune cells by pathogens in terms of mechanisms and systems, explain the complex function of the human immune system.
Hallmarks of Cancer	1	1
Hallmarks of Cancer Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: HOC1VO Contact hours per week: 1 ECTS: 1 Course Content: The history of cancer research Molecular causes of cancer Genetic changes and their causes Fundamental molecular features of cancer development Multi-stage process of cell transformation Tumour-stromal interactions Metastasis Tumour immunology Tumour metabolism Targeted therapies and personalised medicine Tumour engineering and drug development Course outcome: Upon completion of this course students are able to: explain the molecular causes of cancer, explain and analyze the complex events when healthy tissue is transformed into malignant tissue, explain and interpret new therapeutic approaches aimed at treating cancer and immunological disorders.
Molecular Mechanisms of Ageing	1	1
Molecular Mechanisms of Ageing Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: MMA1VO Contact hours per week: 1 ECTS: 1 Course Content: The ageing process in cells The ageing process in living organisms Theories and molecular mechanisms of ageing Genetic programming for ageing Environmental factors and genetic predisposition Premature ageing: selected examples and molecular causes of the condition Lifestyle, stress and hormonal status Age-related diseases and their causes Course outcome: Upon completion of this course students are able to: explain the functional relationships between the genome, embryogenesis, ageing processes, environmental factors and diseases, explain and analyze the complex events in cells an tissues when aging takes place, explain the physiology of ageing and associated diseases.
Developmental Biology	1	1
Developmental Biology Module: Health, Disease and Therapeutical Strategies Root module: Health, Disease and Therapeutical Strategies Semester: 1 Course code: DBIO1VO Contact hours per week: 1 ECTS: 1 Course Content: Fundamentals and mechanisms of embryogenesis Early embryogenesis and topological patterning of the axes (fertilisation, initial cell division, morula, gastrulation and neurulation) Late embryogenesis (organ development from ectoderm, mesoderm and endoderm) Embryonic models for drug development Somatic cell reprogramming and regenerative medicine Course outcome: Upon completion of this course students are able to: analyze the functional relationships between the genome, embryogenesis, ageing processes, environmental factors and diseases, explain the molecular mechanisms of embryogenesis, use embryonic animal models for testing active ingredients.
Bioethics
Bioethics	1	1
Bioethics Module: Bioethics Root module: Bioethics Semester: 1 Course code: BETH1WK Contact hours per week: 1 ECTS: 1 Course Content: The ethics of end-of-life decision making Embryo screening Predictive medicine Transplantation medicine Legal issues Stem cells Assisted dying Moderated discussions on relevant topics Course outcome: Upon completion of this course students are able to: evaluate and discuss social and scientific aspects of applications of genetic engineering as well as bioethical issues, evaluate and find solutions to legal questions related to bioethics, evaluate and apply statutory regulations connected with bioethics and human dignity.
Process Design
Equipment and Production Design	2	3
Equipment and Production Design Module: Process Design Root module: Process Design Semester: 1 Course code: EPD1VO Contact hours per week: 2 ECTS: 3 Course Content: •Specifications (facilities, product, instrumentation), analytical systems (e.g. sensors) Costing and design of utility systems (gas and air supply, water for injection, cooling and heating mediums) IQ, OQ, PQ, URS, process qualification Inspection, acceptance and commissioning of production facilities (cleaning, water runs, sterility and conformity testing) Process standards Media design (complex, defined) including media preparation and sterilisation techniques (in situ, ex situ) Inoculum preparation and fermentation management; microbial organisms vs. mammalian cells Fermentation kinetics (e.g. product formation rate, glucose uptake rate, oxygen requirements and energy input) Students independently complete exercises on media preparation planning, calculation of parameters for reaction kinetics, sterilisation times and microorganism kill rates, and for the efficiency of virus removal steps, as well as preparing sampling plans using the kinetics data to compile batch records. Course outcome: Upon completion of this course students are able to: plan the basic features of biotechnology production facilities, explain standards and families of standards applicable in Austria and abroad, and interpret them accordingly, apply integrated knowledge of production facility design to achieve precisely defined product quality parameters.
Standardization	1	2
Standardization Module: Process Design Root module: Process Design Semester: 1 Course code: ST1VO Contact hours per week: 1 ECTS: 2 Course Content: Overview of the development of company specification standards based on national and international standards Specifications Standards (open, proprietary, basic, product, planning and service) Distinction between specifications, standards, regulation and company standards The standardisation process National standards (ÖNORM, DIN) International standards (ISO, CEN) Structural design of standards Dealing with national and international standards in the course of routine work in the biotechnology industry Legal aspects of standardisation Distinction between standardisation and accreditation The accreditation process Course outcome: Upon completion of this course students are able to: explain standards and families of standards applicable in Austria and abroad, and interpret them accordingly, explain and apply legal aspects of product standardisation based on national and international standards.
Biomedical Regulatiuons
Legislation for Drugs and Medical Devices	2	3
Legislation for Drugs and Medical Devices Module: Biomedical Regulatiuons Root module: Biomedical Regulatiuons Semester: 1 Course code: LDMD1VO Contact hours per week: 2 ECTS: 3 Course Content: Pharmaceuticals legislation in Europe and the US Definition of pharmaceuticals and important distinctions Development and lifecycles of pharmaceuticals Quality aspects of pharmaceuticals, safety and efficacy Structure and content of specialist and patient information Pharmaceuticals approval process in Europe and the US Maintaining approval Generic drugs, internet and product liability Pharmacovigilance Pharmaceuticals marketing and sales Medical Products Act: requirements for medical products (harmonised standards, CE marking, carrying out conformity assessments) Classification of medical products Course outcome: Upon completion of this course students are able to: apply the legislation and related regulatory regimes for pharmaceuticals in Europe and the US (EMDA, FDA), apply statutory guidelines and patent restrictions pertaining to biomedical products during their lifecycle.
Bioprocess Technology
Upstream and Downstream Processing
Upstream Processing	1	2
Upstream Processing Module: Upstream and Downstream Processing Root module: Bioprocess Technology Semester: 1 Course code: UP1VO Contact hours per week: 1 ECTS: 2 Course Content: Students learn about the processes involved in preparing and managing fermentation with microbiological organisms and mammalian cells. The lectures will cover: • Different useful Host Organisms, their advantages and disadvantages • Fermentation kinetics (e.g. product formation rate, glucose fermentation rate, oxygen requirements and energy input) • Calculations describing fermentations (Mass Balancing, Feed Calculations, Heat Generation and Dissipation) • Fermentation process development and scaling based on different parameters Students perform calculations of parameters for reaction kinetics, feeding and heat dissipation based on typical sets of information given in the industrial environment. Course outcome: Upon completion of this course students are able to: explain technical equipment requirements and process parameters, and classify their application principles.
Downstream Processing	1	2
Downstream Processing Module: Upstream and Downstream Processing Root module: Bioprocess Technology Semester: 1 Course code: DP1VO Contact hours per week: 1 ECTS: 2 Course Content: Students learn about the processes involved in preparing and managing downstream processes of recombinant products comming from microbiological organisms and mammalian cells. The lectures will cover: Cell breakup Primary recovery Different separation principles (mainly chromatography but also christallization) and their scaling preparation for fill and finish Course outcome: Upon completion of this course students are able to: explain and design primary recovery steps, design downstream processes including several purification steps, explain the scaling of primary recovery and purification, design preparation for fill and finish.
Recombinant Protein Production - Theory	2	3
Recombinant Protein Production - Theory Module: Bioprocess Technology Root module: Bioprocess Technology Semester: 1 Course code: RPPT1ILV Contact hours per week: 2 ECTS: 3 Course Content: Overview of the most frequently used protein production organisms for research and industrial applications General principles of protein production Impact of biochemical properties of proteins, their amino acids and chemical modifications on protein production and protein purification Comparison and discussion of standard protein purification strategies Course outcome: Upon completion of this course students are able to: name the principles of the key methods of protein purification and compare their advantages and disadvantages, compare biopharmaceutical production and/or purification strategies.
Recombinant Protein Production - Laboratory	4	4
Recombinant Protein Production - Laboratory Module: Bioprocess Technology Root module: Bioprocess Technology Semester: 1 Course code: RPPL1LB Contact hours per week: 4 ECTS: 4 Course Content: Demonstration of the principles of gene expression/protein production in the Pichia pastoris production organism demonstrated using a cytokine Purification of a cytokine Using this protein to learn about typical methods of biochemical analysis for the characterisation of proteins Specific content includes transformation of yeast cells, expression of cytokine genes from an inducible promoter, breaking open cells and obtaining cell extract, purification of the desired protein using affinity chromatography, defining the protein concentration, visualisation of the protein using western blotting, tests to characterise the bioactivity of the protein. Course outcome: Upon completion of this course students are able to: apply their knowledge of the points above in a laboratory environment, independently develop biopharmaceutical production and/or purification strategies.
Research Project in Industry and Master Thesis
Research Project - Preparation	1	1
Research Project - Preparation Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 1 Course code: RPP1WK Contact hours per week: 1 ECTS: 1 Course Content: Updating CVs and covering letters Career and internship opportunities in industry and research Coaching support with research semester applications Course outcome: Upon completion of this course students are able to: develop arguments to support an application and write application documents, identify and analyse the requirements of prospective employers or internship providers, select research projects suited to their chosen future career, evaluate possible future career paths.
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Process Control and Process Online Monitoring	2	3
Process Control and Process Online Monitoring Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 1 Course code: S1_PCPOM1VO Contact hours per week: 2 ECTS: 3 Course Content: Theoretical principles and technical options in process control Theoretical principles of the measurement, control, regulation, properties and operation of probes Selecting and monitoring critical measurement parameters Automated process definition Process mapping Input-process-output diagrams Process flow diagrams Value stream mapping Top-down charts Swimlane diagrams Process performance Process capability and stability Cp and Cpk Sigma quality levels Simulation calculations and practical exercises Course outcome: Upon completion of this course students are able to: explain the monitoring of up-to-date production processes, identify appropriate instrumentation for the online control and monitoring of processes.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Drug Discovery Systems	2	3
Drug Discovery Systems Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 1 Course code: S2_DDS1VO Contact hours per week: 2 ECTS: 3 Course Content: Biochemical and biophysical assays for drug discovery 3D cell culture techniques for drug discovery Development of small molecular weight compounds High-throuput- and high-content screening Marine organisms as sources of new therapeutic agents Course outcome: Upon completion of this course students are able to: explain major principles applied in drug discovery, compare cutting edge drug discovery methods, illustrate and compare methods of characterising newly discovered drugs, summarize the different phases of the drug discovery process.

Course	SWS	ECTS
Integrative Methods in Biotechnology
Biostatistics and Trend Analysis	1	2
Biostatistics and Trend Analysis Module: Integrative Methods in Biotechnology Root module: Integrative Methods in Biotechnology Semester: 2 Course code: BTA2ILV Contact hours per week: 1 ECTS: 2 Course Content: Precision and reliability of confidence limits Significance tests (T-tests, chi squared test, F-test and non-parametric alternatives) Variance analysis (parametric and non-parametric) Trend analysis Analysis of contingency tables Course outcome: Upon completion of this course students are able to: use biostatistics to address common biotechnology questions, explain physical values that have a significant effect on biotechnological processes.
Systems Biology	1	1
Systems Biology Module: Integrative Methods in Biotechnology Root module: Integrative Methods in Biotechnology Semester: 2 Course code: SBIO2ILV Contact hours per week: 1 ECTS: 1 Course Content: The concept of systems biology Areas of overlap with other disciplines and network theories Forthcoming high-throughput technologies Interactions between components of cellular systems Applications of systems biology strategies for the development of therapies and identification of drug targets Course outcome: Upon completion of this course students are able to: explain the complex interactions of biomolecular networks, explain methods for analysing biomolecular networks.
Structural Bioinformatics and Drug Design	2	2
Structural Bioinformatics and Drug Design Module: Integrative Methods in Biotechnology Root module: Integrative Methods in Biotechnology Semester: 2 Course code: SBDD2VO Contact hours per week: 2 ECTS: 2 Course Content: Biomolecules: basic biochemical and biophysical principles Structural alignment of biomolecules Experiment-based structural determination of biomolecules Predicting biomolecular structural features Modelling the 3D structure of biomolecules Principles and common methods of drug design Course outcome: Upon completion of this course students are able to: examine the links between the structure and function of biomolecules, analyse and compare the 3D structure of biomolecules, use calculations for properties of biomolecules, apply selected drug design methods.
Analytical Methods in Life Science
Bioanalytics Laboratory	2	3
Bioanalytics Laboratory Module: Analytical Methods in Life Science Root module: Analytical Methods in Life Science Semester: 2 Course code: BAL2LB Contact hours per week: 2 ECTS: 3 Course Content: Mass spectroscopy gene knock down with siRNA in mammalian cells followed by analysis of the proteome bioinformatic analyis of proteomic data gene clustering and visualization of pathways identification of putative targets Course outcome: Upon completion of the course, students are able to: apply practical organic separation and detection skills and synthesise simple organic compounds, apply documentation on synthesis reactions and estimate the related risks.
Personalized Medicine Laboratory	2	3
Personalized Medicine Laboratory Module: Analytical Methods in Life Science Root module: Analytical Methods in Life Science Semester: 2 Course code: PML2LB Contact hours per week: 2 ECTS: 3 Course Content: DNA and RNA isolation and analysis cDNA synthesis Real-time quantitative PCR (qPCR) with SYBR® Green and TaqMan™ probes (comparison) Gene expression analysis Allele-specific qPCR SNP analysis High-resolution melting curve analysis PCR RFLP Pyrosequencing Course outcome: Upon completion of this course students are able to: apply practical organic separation and detection skills and synthesise simple organic compounds, apply documentation on synthesis reactions and estimate the related risks.
Analytical Methods in Biomedicine	2	3
Analytical Methods in Biomedicine Module: Analytical Methods in Life Science Root module: Analytical Methods in Life Science Semester: 2 Course code: AMB2VO Contact hours per week: 2 ECTS: 3 Course Content: Methods of real-time qPCR (including primer design in the PC lab) and their applications (gene expression analysis, allele-specific qPCR) Methods of identifying genetic variations (e.g. sequencing, pyrosequencing and massive parallel sequencing) – personalised medicine Analysis of epigenetic modifications DNA-protein interactions (ChIP, EMSA, DNase footprint) Flow cytometry Cell fractionation Analysis of post-translational modifications (phosphorylation, glycosylation, ubiquitination) Course outcome: Upon completion of this course students are able to: explain gene expression analyses at the RNA and protein levels, and present them in academic texts, explain epigenetic modifications and formulate hypotheses on their effects, explain methods of practical organic separation.
Fundamentals in Pharmaceutical Sciences
Pharmacokinetics and Pharmacodynamics	2	3
Pharmacokinetics and Pharmacodynamics Module: Fundamentals in Pharmaceutical Sciences Root module: Fundamentals in Pharmaceutical Sciences Semester: 2 Course code: PP2VO Contact hours per week: 2 ECTS: 3 Course Content: General pharmacology Quantifying the effects of pharmaceuticals Concentration-effect relationships for in vitro and in vivo models Characterisation of agonists and antagonists Molecular mechanisms of action and target proteins in pharmaceuticals Types of receptor, receptor subtypes, pharmacodynamic and pharmacokinetic causes of resistance Pharmacological studies in preclinical pharmaceutical development Use of animal models Pharmacological studies in clinical development ADME: fundamental principles of resorption, distribution, metabolism, and excretion of pharmaceuticals Determining ADME parameters in practice Phases of clinical trials Preparation of investigator's brochures Course outcome: Upon completion of this course students are able to: compare the principles and key areas of pharmacodynamics and pharmacokinetics, analyse pharmacodynamic and pharmacokinetic parameters, explain the molecular mechanism of action of pharmaceuticals, evaluate the role of pharmacodynamics and pharmacokinetics as part of pharmaceutical development, summarize how animal models are used in pharmacology.
Quality Management and Regulations in Biotechnology
GLP, GMP and Risk Assessment
GLP and GMP Regulations	1	1
GLP and GMP Regulations Module: GLP, GMP and Risk Assessment Root module: Quality Management and Regulations in Biotechnology Semester: 2 Course code: GGR2VO Contact hours per week: 1 ECTS: 1 Course Content: Statutory quality assurance regulations in the pharmaceutical industry OECD Principles of Good Laboratory Practice (GLP); applicability of the study plan and study report EU Guide to GMP and CFR 210/211; applicability of the GMP regulation Setting up a product facility Regulations relating to personnel, production, documentation, quality control and QM QM during the biotechnological development process Testing of active substances and additives Formulation development, developing production processes; form of administration and container closure systems Microbial controls; compatibility QM in the pharmaceutical industry: ICH Q8,Q9 and Q10 Course outcome: Upon completion of this course students are able to: name and apply statutory pharmaceutical quality assurance regulations applicable in the preclinical, clinical and production phases, explain and apply audit systems.
Risk Assessment	1	1
Risk Assessment Module: GLP, GMP and Risk Assessment Root module: Quality Management and Regulations in Biotechnology Semester: 2 Course code: RA2VO Contact hours per week: 1 ECTS: 1 Course Content: Risk management in accordance with ICH Q9 and other guidelines Methods of risk assessment: preliminary risk analysis: Preliminary hazard analysis (PHA), event tree analysis (ETA), failure mode and effect analysis (FMEA), fault tree analysis (FTA), HAZOP (hazard and operability studies) Corrective measures: HAZOP Critical control point hazard analysis and critical point methodology (HACCP) Risk management and reliability planning, risk assessment for development projects, environmental risk assessment Course outcome: Upon completion of this course students are able to: apply various risk assessment methods in the context of the pharmaceutical and biotechnology industries.
Quality Management Systems	1	1
Quality Management Systems Module: Quality Management and Regulations in Biotechnology Root module: Quality Management and Regulations in Biotechnology Semester: 2 Course code: QMS2VO Contact hours per week: 1 ECTS: 1 Course Content: Quality management systems, standards and guidelines, comparison of ISO, ICH and GMP Statistical methods and elements of QM Principles of QM and its elements Auditing quality management systems; principles and methods Course outcome: Upon completion of this course students are able to: explain and interpret quality assurance methods for pharmaceutical products, explain various aspects of quality management (QM) systems, apply and analyse statistical methods for QM systems, explain and apply audit systems.
Pharmaceutical Project Management
Project and Portfolio Management	1	1
Project and Portfolio Management Module: Pharmaceutical Project Management Root module: Pharmaceutical Project Management Semester: 2 Course code: PPMGT2VO Contact hours per week: 1 ECTS: 1 Course Content: Key aspects of project management in the pharmaceutical industry Portfolio management Corporate strategy Project structure planning, work packages, project network diagrams, critical path analysis Managing integration Developing biotechnological pharmaceuticals Course outcome: Upon completion of this course students are able to: plan and implement pharmaceutical industry projects, generate project plans with work packages.
Clinical Studies and GCP	1	1
Clinical Studies and GCP Module: Pharmaceutical Project Management Root module: Pharmaceutical Project Management Semester: 2 Course code: CSGCP2VO Contact hours per week: 1 ECTS: 1 Course Content: Clinical trials: phases and management Setting up and monitoring clinical trials Quality standards for clinical trials Interface management during trials, academic versus industry-funded research Risk-benefit analysis Investigational product management Project management in clinical trials Course outcome: Upon completion of this course students are able to: evaluate the regulations applicable to particular clinical trials and apply them in the course of the respective project, devise a set-up for carrying out clinical trials.
Entrepreneurship in Life Sciences	2	2
Entrepreneurship in Life Sciences Module: Pharmaceutical Project Management Root module: Pharmaceutical Project Management Semester: 2 Course code: ELS2ILV Contact hours per week: 2 ECTS: 2 Course Content: Students will be introduced to the business side of setting up a new company and key management processes. Business aspects of start-ups: Analysis of the business environment (analysis of the market, environment, location as well as legal, political and technical considerations) Choice of legal form Drawing up a business plan Cost accounting: Designing a cost accounting and cost-type system Cost-centre accounting Cost unit accounting (calculation), analysis of operating profit Management control: Budgeting Budgets and financial plans Objectives, tasks and functions of management control Management indicators Analysing annual financial statements Management case studies Course outcome: Upon completion of this course students are able to: exemplify an overview of business processes, explain underlying legal frameworks, explain how business processes can be managed.
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Fermentation and Scale Up - Scale Down Techniques
Fermentation of Complex Host Systems	1	1
Fermentation of Complex Host Systems Module: Fermentation and Scale Up - Scale Down Techniques Root module: Elective 1: Bioprocess Engineering Semester: 2 Course code: S1_FCHS2VO Contact hours per week: 1 ECTS: 1 Course Content: Fermentation of extremophile organisms Co-cultivation of organisms Mammalian cell fermentation Use of alternative carbon (C) sources with specialised organisms New types of host systems (content selected by the available visiting experts) Course outcome: Upon completion of this course students are able to: analyse and optimise the progress of fermentation and solve problems that arise, operate a process control system and program simple operations.
Scale Up - Scale Down Techniques	1	2
Scale Up - Scale Down Techniques Module: Fermentation and Scale Up - Scale Down Techniques Root module: Elective 1: Bioprocess Engineering Semester: 2 Course code: S1_SUSDT2VO Contact hours per week: 1 ECTS: 2 Course Content: Purification steps for biopharmaceutical products and methods for shifting from laboratory-scale to pilot-plant or production scale processes The four main operations in downstream production: removal of insolubles, product isolation, product purification and product polishing Filtration, lysis and flocculation, sedimentation, extraction, chromatography and adsorption, precipitation, crystallisation, spray drying and centrifugation Dimensionless indicators and an introduction to dimensional analysis Calculation exercises: characterisation of individual purification steps and scaling up elements of facilities Application of scale-down models for process modelling to resolve problems with current production processes Course outcome: Upon completion of this course students are able to: explain common techniques and purification strategies for the production of biopharmaceuticals, explain key requirements for technical equipment, the key process parameters and their determination, as well as the adaptation of process strategies according to the production organism and the properties of the biopharmaceutical product, apply this knowledge in simple examples, analyse problems in relation to the areas mentioned above.
Fermentation Technology - Laboratory I	2	3
Fermentation Technology - Laboratory I Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 2 Course code: S1_FTLI2LB Contact hours per week: 2 ECTS: 3 Course Content: Fermentation of different host systems in different operational modes (Batch, Fed-Batch) Sampling (online, atline and offline) and corresponding analytics Analyzing and judging of analytical data Applying the theoretical knowledge and data to control and optimize the fermentation Primary recovery based on the fermentation process Purifying of recombinant proteins Course outcome: Upon completion of this course students are able to: explain and apply advanced fermentation knowledge to develop and optimize fermentation processes with different host organisms, explain and apply primary recovery knowledge to develop and optimize this process step, explain and apply purification of proteins knowledge to develop and optimize this process step.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Advanced Therapeutic Development Laboratory I	2	3
Advanced Therapeutic Development Laboratory I Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 2 Course code: S2_ATDLI2LB Contact hours per week: 2 ECTS: 3 Course Content: Establishment and validation of Assays for HCS High-throughput Screening: theoretical and practical programming of an HT device (liquid handling & automation Course outcome: Upon completion of this course students are able to: generate and validate complex Assays for HCS, explain, analyse and discuss the latest trends in HCS, programm and use a HT-device.
Pathophysiology and Molecular Therapies	2	3
Pathophysiology and Molecular Therapies Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 2 Course code: S2_PMT2VO Contact hours per week: 2 ECTS: 3 Course Content: Pathology of selected example illnesses State-of-the-art therapy strategies Developing new therapy concepts Standard strategies and future approaches to vaccination Development and application of the latest mouse models Course outcome: Upon completion of this course students are able to: explain/illustrate selected example illnesses and describe their pathophysiology, explain and compare state-of-the-art therapy strategies and new therapy concepts.

Course	SWS	ECTS
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Equipment Test and Process Validation	2	4
Equipment Test and Process Validation Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 3 Course code: S1_ETPV3VO Contact hours per week: 2 ECTS: 4 Course Content: <ul> <li>Fundamentals of equipment, test and process validation based on legal guidelines and using practical examples</li> <li>Design qualification</li> <li>User requirements specification</li> <li>Functional specifications</li> <li>Installation qualification (IQ), drawing up IQ plans</li> <li>Operational qualification (OQ)</li> <li>Drawing up OQ plans</li> <li>Performance qualification</li> <li>Retrospective qualification</li> <li>Requalification</li> <li>Maintaining qualification status</li> <li>Process validation</li> <li>Defining the scope of a validation, risk analysis</li> <li>Validation master plan and validation matrix</li> <li>Cleaning validation</li> <li>Optimising cleaning procedures and drafting cleaning policies</li> <li>Cleaning validation master plan</li> <li>Defining the scope of validation</li> <li>Acceptance criteria, computer validation</li> <li>Prospective and retrospective validation, validation master plan</li> <li>Operating computerised systems</li> </ul> Course outcome: Upon completion of this course students are able to: analyse offline analytical tests for the quality control of biopharmaceuticals, use the knowledge outlined above to optimise processes and identify and solve problems that arise in this context, design test documentation, use and plan equipment and devices in the context of pharmaceutical applications, design experimental designs and parameters for the validation of simple tests and items of equipment, design and evaluate test specifications and reports.
Fermentation Technology - Laboratory II	5	11
Fermentation Technology - Laboratory II Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 3 Course code: S1_FTLII3LB Contact hours per week: 5 ECTS: 11 Course Content: Fermentation of single cell organisms Operating process control systems Working with bioreactors under sterile conditions Offline measurement methods Online measurement methods Calculating fermentation control parameters Preparing defined and complex media Sterile addition methods Troubleshooting Analysis of fermentation parameters Evaluating parameters to arrive at a process management approach Setting up, dismantling and maintaining bioreactors Analytical methods of evaluation (e.g. electrophoresis, FPLC and ELISA) Cell disruption methods Course outcome: Upon completion of this course students are able to: explain basic and andvanced principles of fermentation and the use of fermentation technology in a near-industrial context, apply this knowledge to manage fermentation processes, use fermentation measurement data to inform subsequent process management decisions.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Stem Cells, Gene Therapy and Regenerative Medicine	1	3
Stem Cells, Gene Therapy and Regenerative Medicine Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 3 Course code: S2_SCGTRM3VO Contact hours per week: 1 ECTS: 3 Course Content: Stem cells for therapeutic applications Principles of cell and tissue therapy Principles of gene therapy and its applications Tissue engineering techniques Examples of cell and tissue therapy applications Course outcome: Upon completion of this course students are able to: identify and classify the properties of different types of stem cell, explain the therapeutic applications of stem cells and other types of cell, and discuss the latest trends in stem cell research.
Immunology Based Therapies	1	1
Immunology Based Therapies Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 3 Course code: S2_IBT3VO Contact hours per week: 1 ECTS: 1 Course Content: Key properties of immune cells for immune therapy Immune therapy techniques Examples of immune therapy application Course outcome: Upon completion of this course students are able to: compare therapeutic approaches in regenerative medicine, explain the principles of gene therapy and discuss their application, explain and compare strategies for immune-based therapies.
Advanced Therapeutic Development Laboratory II	5	11
Advanced Therapeutic Development Laboratory II Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 3 Course code: S2_ATDLII3LB Contact hours per week: 5 ECTS: 11 Course Content: Isolation and characterization of a state-of-the-art bioactive, therapeutic biomolecule Quality control of this product Characterisation of the product’s functionality (Cell-based Assays) Course outcome: Upon completion of this course students are able to: use methods for the isolation and characterization of therapeutic agents in the laboratory, examine their function of biomolecules using laboratory experiments, discuss the latest trends in the development of therapeutic agents, identify and evaluate potential fields of application.
Research Project in Industry and Master Thesis
Master Thesis - Part I	1	4
Master Thesis - Part I Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 3 Course code: MTI3DA Contact hours per week: 1 ECTS: 4 Course Content: Writing the proposal for the master thesis Practical work and data analysis Course outcome: Upon completion of this course students are able to: Write a master thesis proposal in accordance with the applicable guidelines, Perform the practical work, Analyze the achieved data, independently carry out a research project on a topical theme in a real-life business, biotechnology and/or biomedical working environment.
Master Thesis - Coaching Seminar I	1	1
Master Thesis - Coaching Seminar I Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 3 Course code: MTCI3TU Contact hours per week: 1 ECTS: 1 Course Content: Discussion, feedback and quality assurance of the master thesis proposal Course outcome: Upon completion of this course students are able to: prepare, plan and discuss a scientific project in an appropriate manner.
Research Project	1	10
Research Project Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 3 Course code: RP3SE Contact hours per week: 1 ECTS: 10 Course Content: Literature research Definition of topic for the master thesis Definition of Scientific Methods for the Master thesis Course outcome: Upon completion of this course students are able to: read and evaluate scientific literature, generate and plan a research project, independently carry out a research project on a topical theme in a real-life business, biotechnology and/or biomedical working environment.

Course	SWS	ECTS
Focal Subject - Elective 1: Bioprocess Engineering
Elective 1: Bioprocess Engineering
Current Issues in Bioprocess Engineering	1	2
Current Issues in Bioprocess Engineering Module: Elective 1: Bioprocess Engineering Root module: Elective 1: Bioprocess Engineering Semester: 4 Course code: S1_CIBE4SE Contact hours per week: 1 ECTS: 2 Course Content: Literature research on the latest trends in the relevant fields Reviewing the relevant literature Presentation of results Discussion of the contents of the literature selected Course outcome: Upon completion of this course students are able to: explain the actual state of research in the corresponding field, apply their knowledge to the actual problems in research and industry.
Focal Subject - Elective 2: Advanced Therapeutics Development
Elective 2: Advanced Therapeutics Development
Current Issues in Advanced Therapeutic Development	1	2
Current Issues in Advanced Therapeutic Development Module: Elective 2: Advanced Therapeutics Development Root module: Elective 2: Advanced Therapeutics Development Semester: 4 Course code: S2_CIATD4SE Contact hours per week: 1 ECTS: 2 Course Content: Literature research on the latest trends in the relevant fields Reviewing the relevant literature Presentation of results Discussion of the contents of the literature selected Course outcome: Upon completion of this course students are able to: explain the actual state of research in the corresponding field, apply their knowledge to the actual problems in research and industry.
Research Project in Industry and Master Thesis
Master Thesis - Part II	1	18
Master Thesis - Part II Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 4 Course code: MTII4DA Contact hours per week: 1 ECTS: 18 Course Content: Practical work and data analysis Summary and evaluation of the scientific data in a master thesis Course outcome: Upon completion of this course students are able to: examine and critically discuss literature related to the topic or research problem, Perform the practical work, compile and evaluate data for the purpose of addressing the research problem/s, discuss and critically reflect on findings, independently complete a scientifc paper in form of the master thesis.
Master Thesis - Coaching Seminar II	1	6
Master Thesis - Coaching Seminar II Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 4 Course code: MTCII4TU Contact hours per week: 1 ECTS: 6 Course Content: Discussion, feedback and quality assurance of the master thesis proposal Course outcome: Upon completion of this course students are able to: prepare, plan and discuss a scientific project in an appropriate manner.
Master Exam	0	4
Master Exam Module: Research Project in Industry and Master Thesis Root module: Research Project in Industry and Master Thesis Semester: 4 Course code: MEX4AP Contact hours per week: 0 ECTS: 4 Course Content: Presentation of the master thesis Oral examination on the Master thesis and links to related subjects on the curriculum Course outcome: Upon completion of this course students are able to: present their master thesis and the question they addressed in a manner appropriate to the target audience, and defend the thesis before an expert committee, outline the significance of the findings for professional practice and research, and present supporting arguments, answer follow-up questions on degree-programme subjects and the links between them, and justify their answers.

Electives

Choose your own focus areas: you select one of two electives on the master programme.

Bioprocess Engineering

This elective prepares you for work in the development and manufacture of pharmaceutical products.

Today, these products are frequently produced using biopharmaceutical techniques, by means of fermentation in large bioreactors. This requires genetically modified microorganisms, which are cultured in very high cell densities to manufacture the desired product. Such products range from medicines to ingredients for nutritional supplements, as well as substances like bioethanol.

If you take this elective, you will gain detailed insights into bioprocess engineering, process automation, and especially fermentation. This expertise will give you the skills required to take on positions at all types of biotech company – large pharmaceutical businesses as well as small start-ups specialising in innovative products such as nutraceuticals. You’ll be able to contribute in a wide range of areas encompassing the development, testing and large-scale manufacturing of brand new substances.

In the bioprocess engineering lectures and practicals you’ll use cutting-edge analytical techniques, ranging from simple online methods – which you’ll also evaluate – through to liquid LC-MS for proteomics work.

Advanced Therapeutics Development

This elective takes an in-depth look at research into active ingredients and their mechanisms. It lays the foundations for a PhD in a related area or a job in an R&D department in the biotech industry.

Medical biotechnology has seen some major breakthroughs in recent years, such as immune checkpoint inhibitors (PD-1) for the treatment of advanced melanomas. Small interfering RNA (siRNA) molecules are currently being tested for use in potential treatments for cancers and viral diseases, which are expected to come on to the market in the next few years.

High-throughput technologies in areas such as next-generation sequencing (NGS), mass spectrometry and imaging are becoming increasingly important in the development of new treatments. This means there is going to be an ever greater focus on linking together large data sets, and integrating the clinical results of treatment.

The Advanced Therapeutic Development elective module gives you a solid grounding in these areas. This is reinforced with a lab-based course linked to the elective, in which you reproduce the early stages of the drug development process. A journal club on topical biotechnology questions rounds out the programme.

Newsletter & additional information

Do you need additional information? Subscribe to your personalised newsletter or order brochures about our courses.

Get additional information now

Download brochure now

Newsletter & brochures

Topics

First name *

This field can not be empty.

Last name *

This field can not be empty.

E-mail *

This field can not be empty.

Language

Yes, I want to receive the selected information from IMC Krems. *

This field can not be empty.

Die mit * makierten Felder sind Pflichtfelder und müssen ausgefüllt werden. Ihre Daten werden selbstverständlich vertraulich behandelt. Wenn Sie sich zum Newsletter anmelden, werden Ihre Daten auch von unserem Auftragsverarbeiter in den USA (MailChimp) verarbeitet. In den USA herrscht kein angemessenes Datenschutzniveau. US-Behörden haben eventuell Zugriff auf Ihre Daten, ohne dass Sie eine adäquate Möglichkeit des Rechtsschutzes haben. Bitte finden Sie die Details zur Verarbeitung Ihrer personenbezogenen Daten in der Datenschutzerklärung insbesondere unter dem Punkt „Newsletterversand“.

* Mandatory fields must be completed. Your data will be treated confidentially. If you register for the newsletter, your data will also be processed by our data processor in the USA (MailChimp). There is no adequate level of data protection in the USA. US authorities may have access to your data without you having an adequate possibility of legal protection. Unsubscribing from the newsletter is possible at any time. You will find the information on our data protection policy here.

Career paths

As a graduate of the Medical and Pharmaceutical Biotechnology master programme you will be especially well placed to assume positions at pharmaceutical and biotechnology companies or medical research institutes.

You can also opt to take a PhD at a university in Austria or abroad. We have PhD cooperation agreements with Danube University Krems and the University of Veterinary Medicine, Vienna. These agreements ensure that admission to the PhD programmes at these institutions is a straightforward process.

The professional areas open to graduates include:
R&D responsibilities in research and industry
clinical trials and drug approval
planning and management of biotechnological processes (fermentation)
biomedical and analytical testing procedures
coordination responsibilities in production, quality control, quality assurance and approval
marketing and sales
medical engineering
food technology and food safety
industrial and environmental biotechnology

10 good reasons

What makes us special? We are more than happy to tell you about the aspects of our university, which we are especially proud of.

Find out more

Krems

Friendly and cosmopolitan: The city attracts students from all over the world, who come to study, research and work together.

Find out more

Service centers

Our university has removed a host of administrative hurdles, leaving you free to concentrate fully on your studies.

Find out more

Advisory Service

Do you have questions regarding our degree programmes or the application? Contact our Prospective Student Advisory Service.

Find out more

Opinions: Medical and Pharmaceutical Biotechnology

Click through the videos of the degree programme.

Get to know our university of applied sciences from a new and very personal perspective.

Multimedia platform Virtual IMC

Our team

Get to know the core team of our master degree programme Medical and Pharmaceutical Biotechnology.

Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger
Head of Institute Biotechnology / Programme Director Medical and Pharmaceutical Biotechnology
Institute Biotechnology
+43 2732 802 521
[email protected]
IMC Campus KremsIMC Campus Trakt G
Recombinant Protein Expression, Cell Culture Models, Peptide Engineering,
Instrument Development
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Immobilisierung von Kameloidantikörper für therapeutische Apherese und für die Unterstützung von Dialyse
Project Leader, Department of Science & Technology
Extrazelluläre Vesikel aus dem Hoffa-Fettkörper - ein neuer Ansatz der Knorpelregeneration?
Department of Science & Technology
Testung von rekombinanten polyklonalen Antikörperfragmenten gegen Gluten-Peptide
Project Leader, Department of Science & Technology
Die Rolle von NFR2 in der Melanomprogression - Einblicke in die Mechanismen von Metastasen
Project Leader, Department of Science & Technology
Etablierung der molekularen Toxikologie für rasche, frühzeitige sowie sensitive Toxizitätsbestimmungen und Biokompatibilität
Project Leader, Department of Science & Technology
Entwicklung einer Design-Pipeline für innovative Protein-Protein-Interaktionshemmer
Department of Science & Technology
MEMESA – Metastasierendes Melanom Spezifische Antikörper
Project Leader, Department of Science & Technology
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Project Leader, Department of Science & Technology
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
Entwicklung neuer Methoden zur Verbesserung von immuntherapeutischen Verfahren in der Onkologie
Department of Science & Technology
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Department of Science & Technology
Etablierung innovativer, vaskulärer Äquivalente zur Entwicklung von Detektionsmodulen für Hochdurchsatz-Verfahren und zur Entwicklung von anti-entzündlichen Peptiden
Project Leader, Department of Science & Technology
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Department of Science & Technology
Biopharm - Isolation bioaktiver Stoffe aus Cyanobakterien
Project Leader, Department of Science & Technology
Zellbasierte Testsysteme für bioaktive Substanzen
Project Leader, Department of Science & Technology
Colleselli, K., Ebeyer-Masotta, M., Neuditschko, B., Stierschneider, A., Pollhammer, C., Potocnjak, M., Hundsberger, H., Herzog, F., Wiesner, C. (2023): Beyond Pattern Recognition: TLR2 Promotes Chemotaxis, Cell Adhesion, and Migration in THP-1 Cells. Cells, 12(10): 1425.
Doi: https://doi.org/10.3390/cells12101425
Stierschneider, A., Neuditschko, B., Colleselli, K., Hundsberger, H., Herzog, F., & Wiesner, C. (2023): Comparative and Temporal Characterization of LPS and Blue-Light-Induced TLR4 Signal Transduction and Gene Expression in Optogenetically Manipulated Endothelial Cells. Cells, 12(697).
Doi: https://doi.org/10.3390/cells12050697
Lucas, R., Hadizamani, Y., Enkhbaatar, P., Csanyi, G., Caldwell, R. W., Hundsberger, H., Sridhar, S., Lever, A. A., Hudel, M., Ash, D., Ushio-Fukai, M., Fukai, T., Chakraborty, T., Verin, A., Eaton, D. C., Romero, M., & Hamacher, J. (2022): Dichotomous Role of Tumor Necrosis Factor in Pulmonary Barrier Function and Alveolar Fluid Clearance. Frontiers in Physiology, 12: 793251.
Doi: https://doi.org/10.3389/fphys.2021.793251
Weitzenböck, HP., Gschwendtner, A., Wiesner, C., Depke, M., Schmidt, F., Trautinger, F., Hengstschläger, M., Hundsberger, H., Mikula, M. (2022): Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment. Cancer Medicine, 11(4): 956-967.
Doi: https://doi.org/10.1002/cam4.4506
Stierschneider, A., Grünstäudl, P., Colleselli, K., Atzler, J., Klein, C., Hundsberger, H., Wiesner, C. (2021): Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line. International Journal of Molecular Sciences, 22(17): 9232.
Doi: https://doi.org/10.3390/ijms22179232
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Kinslechner, K., Schütz, B., Pistek, M., Rapolter, P., Weitzenböck, H. P., Hundsberger, H., Mikulits, W., Grillari, J., Röhrl, C., Hengstschläger, M., Stangl, H., & Mikula, M. (2019): Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma. International journal of molecular sciences, 20(5): 1063.
Doi: https://doi.org/10.3390/ijms20051063
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Hundsberger, H., Önder, K., Schuller-Götzburg, P., Virok, D. P., Herzog, J., & Rid, R. (2017): Assembly and use of high-density recombinant peptide chips for large-scale ligand screening is a practical alternative to synthetic peptide libraries. BMC genomics, 18(1): 450.
Doi: https://doi.org/10.1186/s12864-017-3814-3
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Volk, K., Breunig, S. D., Rid, R., Herzog, J., Bräuer, M., Hundsberger, H., Klein, C., Müller, N., & Önder, K. (2017): Structural analysis and interaction studies of acyl-carrier protein (acpP) of Staphylococcus aureus, an extraordinarily thermally stable protein. Biological chemistry, 398(1): 125-133.
Doi: https://doi.org/10.1515/hsz-2016-0185
Schütz, B., Koppensteiner, A., Schörghofer, D., Kinslechner, K., Timelthaler, G., Eferl, R., Hengstschläger, M., Missbichler, A., Hundsberger, H., & Mikula, M. (2016): Generation of metastatic melanoma specific antibodies by affinity purification. Scientific reports, 6: 37253.
Doi: https://doi.org/10.1038/srep37253
Al-Harthy, T., Zoghaib, W. M., Pflüger, M., Schöpel, M., Önder, K., Reitsammer, M., Hundsberger, H., Stoll, R., & Abdel-Jalil, R. (2016): Design, Synthesis, and Cytotoxicity of 5-Fluoro-2-methyl-6-(4-aryl-piperazin-1-yl) Benzoxazoles. Molecules, 21(10): 1290.
Doi: https://doi.org/10.3390/molecules21101290
Al-Harthy, T., Abdel-Jalil, R., Zoghaib, W., Pflüger, M., Hofmann, E., & Hundsberger, H. (2016): Design and synthesis of benzothiazole schiff bases of potential antitumor activity. Heterocycles, 92(7): 1282-1292.
Doi: https://doi.org/10.3987/COM-16-13471
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Herzog, J., Rid, R., Wagner, M., Hundsberger, H., Eger, A., Bauer, J., & Önder, K. (2015): Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways. BMC research notes, 8: 785.
Doi: https://doi.org/10.1186/s13104-015-1783-7
Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929
Rid, R., Hundsberger, H., & Onder, K. (2014): Compound screening and transcriptional profiling in human primary keratinocytes: a brief guideline. Methods in molecular biology, 1195: 99-109.
Doi: https://doi.org/10.1007/7651_2013_50
Kapuścik, A., Hrouzek, P., Kuzma, M., Bártová, S., Novák, P., Jokela, J., Pflüger, M., Eger, A., Hundsberger, H., Kopecký, J. (2013): Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem : a European journal of chemical biology, 14(17): 2329-2337.
Doi: https://doi.org/10.1002/cbic.201300246
Rid, R., Herzog, J., Maier, R. H., Hundsberger, H., Eger, A., Hintner, H., Bauer, J. W., Onder, K. (2013): Real-time monitoring of relative peptide-protein interaction strengths in the yeast two-hybrid system. Assay and drug development technologies, 11(4): 269-275.
Doi: https://doi.org/10.1089/adt.2012.496
Rid, R., Wagner, M., Maier, C. J., Hundsberger, H., Hintner, H., Bauer, J. W., & Onder, K. (2013): Deciphering the calcitriol-induced transcriptomic response in keratinocytes: presentation of novel target genes. Journal of molecular endocrinology, 50(2): 131–149.
Doi: https://doi.org/10.1530/JME-11-0191
Kreiseder, B., Orel, L., Bujnow, C., Buschek, S., Pflueger, M., Schuett, W., Hundsberger, H., de Martin, R., Wiesner, C. (2013): α‐Catulin downregulates E‐cadherin and promotes melanoma progression and invasion. International journal of cancer, 132(3): 521-530.
Doi: https://doi.org/10.1002/ijc.27698
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
Khare, V., Lyakhovich, A., Dammann, K., Lang, M., Borgmann, M., Tichy, B., Pospisilova, S., Luciani, G., Campregher, C., Evstatiev, R., Pflueger, M., Hundsberger, H., & Gasche, C. (2013): Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochemical Pharmacology, 85(2): 234-244.
Doi: https://doi.org/10.1016/j.bcp.2012.10.026
Maier, C., Maier, R., Rid, R., Trost, A., Hundsberger, H., Eger, A., Hintner, H., Bauer, J., Onder, K. (2012): PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling. BMC molecular biology, 13: 18.
Doi: https://doi.org/10.1186/1471-2199-13-18
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D., Wendel, A., Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in Bioscience, 13: 5374-86.
Doi: https://doi.org/10.2741/3087
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D. N., Wendel, A., & Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in bioscience : a journal and virtual library, 13: 5374–5386.
Doi: https://doi.org/10.2741/3087
Wiesner, C., Pflueger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schuett, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene interdisziplinar, 3(1).
Wiesner, C., Pflüger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schütt, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene Interdisziplinär, 3(1): Doc05.
Wiesner, C., Lucas, R., Pflueger, M., Kleber, C., Kopecky, J., Stys, D., Entler, B., Hundsberger, H., Atzler, J., Hrouzek, P., Lukesova, A., Schuett, W., (2007): Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites. Drug Metabolism Letters, 1(4): 254-260.
Doi: https://doi.org/10.2174/187231207783221385
Lucas, R., Hundsberger, H., Pflueger, M., Fischer, B., Morel, D., Braun, C., Wendel, A., Chakraborty, T., Schuett, W., Wiesner, C., Hamacher, J. (2007): The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug. Letters in Drug Design & Discovery, 4(5): 336-340.
Doi: https://doi.org/10.2174%2F157018007780867816
Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger
Head of Institute Biotechnology / Programme Director Medical and Pharmaceutical Biotechnology
Head of Institute Biotechnology / Programme Director Medical and Pharmaceutical Biotechnology
Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger
Core Competencies
- Recombinant Protein Expression, Cell Culture Models, Peptide Engineering,
- Instrument Development

DI (FH) Anita Koppensteiner
Scientist Institute Applied Chemistry
Institute Applied Chemistry
+43 2732 802 527
[email protected]
IMC Campus KremsIMC Campus Trakt D
Protein Production, Purification and Analysis
Cell-Based Assays/Microscopy
Biochemical Test Methods and Analysis
Applied Chemistry
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Die Rolle von NFR2 in der Melanomprogression - Einblicke in die Mechanismen von Metastasen
Department of Science & Technology
Extremophiles
Department of Science & Technology
MEMESA – Metastasierendes Melanom Spezifische Antikörper
Department of Science & Technology
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Department of Science & Technology
Etablierung innovativer, vaskulärer Äquivalente zur Entwicklung von Detektionsmodulen für Hochdurchsatz-Verfahren und zur Entwicklung von anti-entzündlichen Peptiden
Department of Science & Technology
Rassy, W., Ripper, D., Pomare, E., Winkler, S., Koppensteiner, A., Spadiut O.,Schild, D. (2023): Incorporation of ionic rare earth elements as a form of microbial environmental remediation. Frontiers in Environmental Science, 11(Section Toxicology, Pollution and the Environment).
Doi: https://doi.org/10.3389/fenvs.2023.1112612
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Schütz, B., Koppensteiner, A., Schörghofer, D., Kinslechner, K., Timelthaler, G., Eferl, R., Hengstschläger, M., Missbichler, A., Hundsberger, H., & Mikula, M. (2016): Generation of metastatic melanoma specific antibodies by affinity purification. Scientific reports, 6: 37253.
Doi: https://doi.org/10.1038/srep37253
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
DI (FH) Anita Koppensteiner
Scientist Institute Applied Chemistry
Hon.Prof.(FH) Mag. Alfred Siedl
Lecturer Institute Business Administration and Management
Institute Business Administration and Management
+43 2732 802
[email protected]
Statistics, Business Mathematics
MS Office, SPSS, GeoGebra
Betriebswirtschaft für das Gesundheitswesen
Bachelor of Arts in Business / part-time
Betriebswirtschaft für das Gesundheitswesen
Bachelor of Arts in Business / full-time
Tourism and Leisure Management
Bachelor of Arts in Business / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Business Administration
Bachelor of Arts in Business / full-time
Hon.Prof.(FH) Mag. Alfred Siedl
Lecturer Institute Business Administration and Management
Prof.(FH) Dr. Barbara Entler
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 361
[email protected]
IMC Campus KremsIMC Campus Trakt G
Microbiology
Microbial Monitoring
Genetic Engineering
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
EvoFerm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Moritz, B., Locatelli, V., Niess, M., Bathke, A., Kiessig, S., Entler, B., Finkler, C., Wegele, H., & Stracke, J. (2017): Optimization of capillary zone electrophoresis for charge heterogeneity testing of biopharmaceuticals using enhanced method development principles. Electrophoresis, 38(24): 3136–3146.
Doi: https://doi.org/10.1002/elps.201700145
Wiesner, C., Pflueger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schuett, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene interdisziplinar, 3(1).
Wiesner, C., Pflüger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schütt, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene Interdisziplinär, 3(1): Doc05.
Wiesner, C., Lucas, R., Pflueger, M., Kleber, C., Kopecky, J., Stys, D., Entler, B., Hundsberger, H., Atzler, J., Hrouzek, P., Lukesova, A., Schuett, W., (2007): Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites. Drug Metabolism Letters, 1(4): 254-260.
Doi: https://doi.org/10.2174/187231207783221385
Prof.(FH) Dr. Barbara Entler
Professor (FH) Institute Biotechnology
Prof.(FH) DI Bernhard Klausgraber
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 348
[email protected]
IMC Campus KremsIMC Campus Trakt G
Inorganic and Organic Chemistry
Microbiology
Fermentation Development and Optimization
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Synthese und industrielle Verwendung von Hydroxytyrosol
Department of Science & Technology
Extremophiles
Project Leader, Department of Science & Technology
Co-Kultivierung von Mikroorganismen
Department of Science & Technology
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Department of Science & Technology
Prof.(FH) DI Bernhard Klausgraber
Professor (FH) Institute Biotechnology
Prof.(FH) Dr. Christian Klein
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 522
[email protected]
IMC Campus KremsIMC Campus Trakt G
Computer-Aided Drug Design
Biochemical Systems Theory
Molecular Modeling and Chemoinformatics
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
EvoFerm
Department of Science & Technology
Spike-Fermentation
Department of Science & Technology
Entwicklung von therapeutischen Peptiden für Krebs- und regenerative Medizin
Department of Science & Technology
Entwicklung einer Design-Pipeline für innovative Protein-Protein-Interaktionshemmer
Project Leader, Department of Science & Technology
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Department of Science & Technology
Stierschneider, A., Grünstäudl, P., Colleselli, K., Atzler, J., Klein, C., Hundsberger, H., Wiesner, C. (2021): Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line. International Journal of Molecular Sciences, 22(17): 9232.
Doi: https://doi.org/10.3390/ijms22179232
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Ablinger, C., Geisler, S. M., Stanika, R. I., Klein, C. T., & Obermair, G. J. (2020): Neuronal α2δ proteins and brain disorders. Pflugers Archiv : European journal of physiology, 472(7): 845-863.
Doi: https://doi.org/10.1007/s00424-020-02420-2
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Volk, K., Breunig, S. D., Rid, R., Herzog, J., Bräuer, M., Hundsberger, H., Klein, C., Müller, N., & Önder, K. (2017): Structural analysis and interaction studies of acyl-carrier protein (acpP) of Staphylococcus aureus, an extraordinarily thermally stable protein. Biological chemistry, 398(1): 125-133.
Doi: https://doi.org/10.1515/hsz-2016-0185
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C.T., Kraemer, O., Himmelsbach, F., Haaksma, E., Adolf, G. R. (2012): Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. Journal of Pharmacology and Experimental Therapeutics, 343(2): 342-350.
Doi: https://doi.org/10.1124/jpet.112.197756
Klein, C.T., Kaiser, D., Ecker, G. (2004): 3D Topolgical Distance-Based Descriptors for Use in QSAR and Diversity Analysis. Journal of Chemical Information and Computer Sciences, 44(1): 200-209.
Doi: https://doi.org/10.1021/ci0256236
Klein, C.T., Kaiser, D., Kopp, S., Chiba, P., Ecker, G. (2002): Similarity-Based SAR as Tool for Early ADME Profiling. Journal of Computer-Aided Molecular Design, 16: 785-793.
Doi: https://doi.org/10.1023/A:1023828527638
Klein, C.T., Kaiblinger, N., Wolschann, P. (2002): Internally Defined Distances in 3D-Quantitative Structure-Activity Relationships. Journal of Computer-Aided Molecular Design, 16: 79-93.
Doi: https://doi.org/10.1023/A:1016308417830
Mayer, B., Klein, C.T. (2000): Influence of Solvation on the Helix Forming Tendency of Nonpolar Amino Acids. Journal of Molecular Structure: THEOCHEM, 532(1-3): 213-226.
Doi: https://doi.org/10.1016/S0166-1280(00)00559-5
Buchbauer, G., Klein, C.T., Wailzer, B., Wolschann, P. (2000): Threshold-Based Structure-Activity Relationships of Pyrazines with Bell Pepper Flavor. Journal of Agricultural and Food Chemistry, 48(9): 4273-4278.
Doi: https://doi.org/10.1021/jf000192h
Klein, C.T., Polheim, D., Viernstein, H., Wolschann, P. (2000): A Method for Estimation of the Free Energies of Complexation between ß-Cyclodextrin and Guest Molecules. Journal of Inclusion Phenomena, 36(4): 409-423.
Doi: https://doi.org/10.1023/A:1008063412529
Klein, C.T., Pircher, H., Wailzer, B., Buchbauer, G., Wolschann, P. (2000): Quantitative Structure-Property Study on Pyrazines with Bell Peper Flavor. Scientific Pharmaceutica, 68(1): 41-56.
Doi: https://doi.org/10.3797/scipharm.aut-00-04
Klein, C.T., Lawtrakul, L., Hannongbua, S., Wolschann, P. (2000): Accessible Charges as Sensitive Descriptors in Structure-Activity Relationships. A Study on HEPT-based HIV-1 RT Inhibitors. Scientific Pharmaceutica, 68(1): 25-40.
Doi: https://doi.org/10.3797/scipharm.aut-00-03
Klein, C.T., Viernstein, H., Wolschann, P. (2000): Free Energy Prediction of Complexation between ß-Cyclodextrin and Guest Molecules: External Predictivity of MR and PLS Models. Scientific Pharamaceutica, 68(1): 15-24.
Doi: https://doi.org/10.3797/scipharm.aut-00-02
Klein, C.T., Polheim, D., Viernstein, H., Wolschann, P. (2000): Predicting the Free Energies of Complexation between Cyclodextrins and Guest Molecules: Linear versus Nonlinear Models. Pharamaceutical Research, 17: 358-365.
Doi: https://doi.org/10.1023/A:1007565409407
Mayer, B., Klein, C.T., Köhler, G. (1999): Selective Assembly of Cyclodextrins on Poly(ethylene oxide) Poly(propylene oxide) Copolymers. Journal of Computer-Aided Molecular Design, 13: 373-383.
Doi: https://doi.org/10.1023/A:1008095501870
Klein, C.T., Mayer, B. (1999): Sources for Switches and Structure Formation in Metabolic Pathways. Biosystems, 51(1): 41-52.
Doi: https://doi.org/10.1016/S0303-2647(99)00012-X
Klein, C.T., Mayer, B., Köhler, G., Wolschann, P. (1998): Systematic Stepsize Variation: An Efficient Method for Searching the Conformational Space of Polypeptides. Journal of Computational Chemistry, 19(13): 1470-1481.
Doi: https://doi.org/10.1002/(SICI)1096-987X(199810)19:13<1470::AID-JCC4>3.0.CO;2-N
Klein, C.T. (1998): Hysteresis-Driven Pattern Formation in Biochemical Networks. Journal of Theoretical Biology, 194(2): 263-274.
Doi: https://doi.org/10.1006/jtbi.1998.0757
Mayer, B., Marconi, G., Klein, C.T., Köhler, G., Wolschann, P. (1997): Structural Analysis of Host–Guest Systems. Methyl-substituted Phenols in beta;-Cyclodextrin. Journal of inclusion phenomena and molecular recognition in chemistry, 29: 79-93.
Doi: https://doi.org/10.1023/A:1007920606983
Klein, C.T., Mayer, B. (1997): A Model for Pattern Formation in Gap-Junction Coupled Cells. Journal of Theoretical Biology, 186(1): 107-115.
Doi: https://doi.org/10.1006/jtbi.1996.0337
Grabner, G., Monti, S., Marconi, G., Mayer, B., Klein, C.T., Köhler, G. (1997): Spectroscopic and Photochemical Study of Inclusion Complexes of Dimethoxybenzenes with Cyclodextrins. The Journal of Physical Chemistry , 100(51): 20068-20075.
Doi: https://doi.org/10.1021/jp962231r
Marconi, G., Mayer, B., Klein, C.T., Köhler, G. (1996): The structure of higher order C60-fullerene-γ-cyclodextrin complexes. Chemical Physics Letters, 260(5-6): 589-594.
Doi: https://doi.org/10.1016/0009-2614(96)00915-3
Köhler, G., Grabner, G., Klein, C.T., Marconi, G., Mayer, B., Monti, S., Rechthaler, K., Rotkiewicz, K., Viernstein, H., Wolschann, P. (1996): Structure and spectroscopic Properties in Cyclodextrin Inclusion Complexes. In Szejtli, J., Szente, L. (Hrsg.), Proceedings of the Eighth International Symposium on Cyclodextrins (215-220). Budapest, Hungary: Springer, Dordrecht.
Doi: https://doi.org/10.1007/978-94-011-5448-2_46
Klein, C.T., Mayer, B., Köhler, G., Wolschann, P. (1996): Influence of solvation on helix formation of poly-alanine studied by multiple annealing simulations. Journal of Molecular Structure: THEOCHEM, 372(1): 33-43.
Doi: https://doi.org/10.1016/S0166-1280(96)04745-8
Klein, C. T., & Seelig, F. F. (1995): Turing structures in a system with regulated gap-junctions. Bio Systems, 35(1): 15–23.
Doi: https://doi.org/10.1016/0303-2647(94)01478-p
Klein, C.T., Mayer, B., Köhler, G., Mraz, K., Reiter, S., Viernstein, H., Wolschann, P. (1995): Solubility and Molecular Modeling of Triflumizole-ß-cyclodextrin Inclusion Complexes. Journal of inclusion phenomena and molecular recognition in chemistry, 22: 15–32.
Doi: https://doi.org/10.1007/BF00706495
Prof.(FH) Dr. Christian Klein
Professor (FH) Institute Biotechnology
Prof.(FH) Priv.Doz. Dr. Reinhard Klein
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 883
[email protected]
IMC Campus KremsIMC Campus Trakt G
Virology
Molecular biology
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
EvoFerm
Department of Science & Technology
In-Vivo-RNA Interferenzstrategien gegen Adenoviren
Project Leader, Department of Science & Technology
Virale und fungale Infektionen
Project Leader, Department of Science & Technology
RNA Interferenz als Methode zur Inhibierung von Virusinfektionen
Project Leader, Department of Science & Technology
Selb, R., Derntl, C., Klein, R., Alte, B., Hofbauer, C., Kaufmann, M., Beraha, J., Schöner, L., & Witte, A. (2017): The Viral Gene ORF79 Encodes a Repressor Regulating Induction of the Lytic Life Cycle in the Haloalkaliphilic Virus ϕCh1. Journal of virology, 91(9): e00206-17.
Doi: https://doi.org/10.1128/JVI.00206-17
Derntl, C., Selb, R., Klein, R., Alte, B., & Witte, A. (2015): Genomic manipulations in alkaliphilic haloarchaea demonstrated by a gene disruption in Natrialba magadii. FEMS microbiology letters, 362(21): fnv179.
Doi: https://doi.org/10.1093/femsle/fnv179
Derntl, C., Selb, R., Klein, R., Alte, B., & Witte, A. (2015): Genomic manipulations in alkaliphilic haloarchaea demonstrated by a gene disruption in Natrialba magadii. FEMS microbiology letters, 362(21): fnv179.
Doi: https://doi.org/10.1093/femsle/fnv179
Bellutti, F., Kauer, M., Kneidinger, D., Lion, T., & Klein, R. (2015): Identification of RISC-associated adenoviral microRNAs, a subset of their direct targets, and global changes in the targetome upon lytic adenovirus 5 infection. Journal of virology, 89(3): 1608–1627.
Doi: https://doi.org/10.1128/JVI.02336-14
Bellutti, F., Kauer, M., Kneidinger, D., Lion, T., & Klein, R. (2015): Identification of RISC-associated adenoviral microRNAs, a subset of their direct targets, and global changes in the targetome upon lytic adenovirus 5 infection. Journal of virology, 89(3): 1608–1627.
Doi: https://doi.org/10.1128/JVI.02336-14
Ibrišimović, M., Lion, T., & Klein, R. (2013): Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovir. BMC biotechnology, 13(1): 54.
Doi: https://doi.org/10.1186/1472-6750-13-54
Mayrhofer-Iro, M., Ladurner, A., Meissner, C., Derntl, C., Reiter, M., Haider, F., Dimmel, K., Rössler, N., Klein, R., Baranyi, U., Scholz, H., & Witte, A. (2013): Utilization of virus φCh1 elements to establish a shuttle vector system for Halo(alkali)philic Archaea via transformation of Natrialba magadii. Applied and environmental microbiology, 79(8): 2741–2748.
Doi: https://doi.org/10.1128/AEM.03287-12
Ibrišimović, M., Kneidinger, D., Lion, T., & Klein, R. (2013): An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs. Antiviral research, 97(1): 10–23.
Doi: https://doi.org/10.1016/j.antiviral.2012.10.008
Kneidinger, D., Ibrišimović, M., Lion, T., & Klein, R. (2012): Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral research, 94(3): 195–207.
Doi: https://doi.org/10.1016/j.antiviral.2012.03.011
Ibrišimović, M., Nagl, U., Kneidinger, D., Rauch, M., Lion, T., & Klein, R. (2012): Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro. The journal of gene medicine, 114(1): 3–19.
Doi: https://doi.org/10.1002/jgm.1638
Klein, R., Rössler, N., Iro, M., Scholz, H., & Witte, A. (2012): Haloarchaeal myovirus φCh1 harbours a phase variation system for the production of protein variants with distinct cell surface adhesion specificities. Molecular microbiology, 83(1): 137–150.
Doi: https://doi.org/10.1111/j.1365-2958.2011.07921.x
Klein, R., Ruttkowski, B., Schwab, S., Peterbauer, T., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2008): Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo. Journal of biomedicine & biotechnology, 2008(683505 ): 10.
Doi: https://doi.org/10.1155/2008/683505
Agu, C. A., Klein, R., Lengler, J., Schilcher, F., Gregor, W., Peterbauer, T., Bläsi, U., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2007): Bacteriophage-encoded toxins: the lambda-holin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells. Cellular microbiology, 9(7): 1753–1765.
Doi: https://doi.org/10.1111/j.1462-5822.2007.00911.x
Iro, M., Klein, R., Gálos, B., Baranyi, U., Rössler, N., & Witte, A. (2007): The lysogenic region of virus phiCh1: identification of a repressor-operator system and determination of its activity in halophilic Archaea. xtremophiles : life under extreme conditions, 11(2): 383–396.
Doi: https://doi.org/10.1007/s00792-006-0040-3
Klein, R., Ruttkowski, B., Knapp, E., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2006): WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene, 372: 153–161.
Doi: https://doi.org/10.1016/j.gene.2005.12.018
Hand, N. J., Klein, R., Laskewitz, A., & Pohlschröder, M. (2006): Archaeal and bacterial SecD and SecF homologs exhibit striking structural and functional conservation. Journal of bacteriology,, 188(4): 1251–1259.
Doi: https://doi.org/10.1128/JB.188.4.1251-1259.2006
Agu, C. A., Klein, R., Schwab, S., König-Schuster, M., Kodajova, P., Ausserlechner, M., Binishofer, B., Bläsi, U., Salmons, B., Günzburg, W. H., & Hohenadl, C. (2006): The cytotoxic activity of the bacteriophage lambda-holin protein reduces tumour growth rates in mammary cancer cell xenograft models. The journal of gene medicine, 8(2): 229–241.
Doi: https://doi.org/10.1002/jgm.833
Mangold, M., Siller, M., Roppenser, B., Vlaminckx, B. J., Penfound, T. A., Klein, R., Novak, R., Novick, R. P., & Charpentier, E. (2004): Synthesis of group A streptococcal virulence factors is controlled by a regulatory RNA molecule. Molecular microbiology, 53(5): 1515–1527.
Doi: https://doi.org/10.1111/j.1365-2958.2004.04222.x
Rössler, N., Klein, R., Scholz, H., & Witte, A. (2004): Inversion within the genome of the haloalkaliphilic virus phiCh1 results in differential expression of structural proteins. Molecular microbiology, 52(2): 413–426.
Doi: https://doi.org/10.1111/j.1365-2958.2003.03983.x
Klein, R., Baranyi, U., Rössler, N., Greineder, B., Scholz, H., & Witte, A. (2002): Natrialba magadii virus fCh: First complete nucleotide sequence and functional organization of a virus infecting an extreme haloalkaliphilic archaeon. Molecular microbiology, 45(3): 851–863.
Doi: https://doi.org/10.1046/j.1365-2958.2002.03064.x
Klein, R., Greineder, B., Baranyi, U., & Witte, A. (2000): The structural protein E of the archaeal virus phiCh1: evidence for processing in Natrialba magadii during virus maturation. Virology, 276(2): 376–387.
Doi: https://doi.org/10.1006/viro.2000.0565
Baranyi, U., Klein, R., Lubitz, W., Krüger, D. H., & Witte, A. (2000): The archaeal halophilic virus-encoded Dam-like methyltransferase M. phiCh1-I methylates adenine residues and complements dam mutants in the low salt environment of Escherichia coli. Molecular microbiology, 35(5): 1168–1179.
Doi: https://doi.org/10.1046/j.1365-2958.2000.01786.x
Katinger, A., Lubitz, W., Szostak, M. P., Stadler, M., Klein, R., Indra, A., Huter, V., & Hensel, A. (1999): Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. Journal of biotechnology, 73(2-3): 251–260.
Doi: https://doi.org/10.1016/s0168-1656(99)00143-1
Witte, A., Baranyi, U., Klein, R., Sulzner, M., Luo, C., Wanner, G., Krüger, D. H., & Lubitz, W. (1997): Characterization of Natronobacterium magadii phage phi Ch1, a unique archaeal phage containing DNA and RNA. Molecular microbiology, 23(3): 603–616.
Doi: https://doi.org/10.1046/j.1365-2958.1997.d01-1879.x
Szostak, M. P., Hensel, A., Eko, F. O., Klein, R., Auer, T., Mader, H., Haslberger, A., Bunka, S., Wanner, G., & Lubitz, W. (1996): Bacterial ghosts: non-living candidate vaccines. Journal of biotechnology, 44(1-3): 161–170.
Doi: https://doi.org/10.1016/0168-1656(95)00123-9
Prof.(FH) Priv.Doz. Dr. Reinhard Klein
Professor (FH) Institute Biotechnology
Prof.(FH) Mag. Dana Mezricky
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 322
[email protected]
IMC Campus KremsIMC Campus Trakt G
GMP/GLP
Molecular Biology
Proteinchemistry / Immunology/ Biochemical Analytics Methods
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
EvoFerm
Department of Science & Technology
Spike-Fermentation
Department of Science & Technology
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Extremophiles
Department of Science & Technology
Co-Kultivierung von Mikroorganismen
Department of Science & Technology
Nahlik,V., Cizkova,M., Singh,A., Mezricky,D., Rucki,M., Andresen,E., Vitova,M. (2022): Growth of the Red Alga Galdieria suphuraria in Re Mud-Containing Medium and Accumulation of Rare Earth Elements. Springer Nature: Waste and Biomass Valorization , 13(12, Dezember 2022): -.
Doi: https://doi.org/10.1007/s12649-022-02021-3
Náhlík, V., Zachleder, V., Čížková, M., Bišová, K., Singh, A., Mezricky, D., Řezanka, T., Vítová, M. (2021): Growth under Different Trophic Regimes and Synchronization of the Red Microalga Galdieria sulphuraria. Biomolecules, 11(7)(939).
Čížková, M., Mezricky, P., Mezricky, D., Rucki, M., Zachleder, V., Vítová, M. (2020): Bioaccumulation of Rare Earth Elements from Waste Luminophores in the Red Algae, Galdieria phlegrea. Waste Biomass Valor.
Doi: https://doi.org/10.1007/s12649-020-01182-3
Rezanka, T., Rezanka, M., Mezricky, D., Vítova, M. (2020): Lipidomic analysis of diatoms cultivated with silica nanoparticles. Phytochemistry, 177: 112452.
Doi: https://doi.org/10.1016/j.phytochem.2020.112452
Čížková, M., Mezricky, D., Rucki, M., Tóth, T. M., Náhlík, V., Lanta, V., Bišová, K., Zachleder, V., & Vítová, M. (2019): Bio-mining of Lanthanides from Red Mud by Green Microalgae. Molecules , 24(7): 1356.
Doi: https://doi.org/10.3390/molecules24071356
Řezanka, T., Kaineder, K., Mezricky, D., Řezanka, M., Bišová, K., Zachleder, V., & Vítová, M. (2016): The effect of lanthanides on photosynthesis, growth, and chlorophyll profile of the green alga Desmodesmus quadricauda. Photosynthesis Research, 130(1-3): 335-346.
Doi: https://doi.org/10.1007/s11120-016-0263-9
Prof.(FH) Mag. Dana Mezricky
Professor (FH) Institute Biotechnology
Prof.(FH) DI Dominik Schild
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 501
[email protected]
IMC Campus KremsIMC Campus Trakt G
Fermentation development
Biochemical Engineering
Process engineering
Applied Chemistry
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
EvoFerm
Project Leader, Department of Science & Technology
Spike-Fermentation
Project Leader, Department of Science & Technology
Theraferm
Project Leader, Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Project Leader, Department of Science & Technology
Synthese und industrielle Verwendung von Hydroxytyrosol
Project Leader, Department of Science & Technology
Extremophiles
Department of Science & Technology
Co-Kultivierung von Mikroorganismen
Project Leader, Department of Science & Technology
Zellbasierte Testsysteme für bioaktive Substanzen
Department of Science & Technology
Rassy, W., Ripper, D., Pomare, E., Winkler, S., Koppensteiner, A., Spadiut O.,Schild, D. (2023): Incorporation of ionic rare earth elements as a form of microbial environmental remediation. Frontiers in Environmental Science, 11(Section Toxicology, Pollution and the Environment).
Doi: https://doi.org/10.3389/fenvs.2023.1112612
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Amer, H., Mimini, V., Schild, D., Rinner, U., Bacher, H., Potthast, A., Rosenau, T. (2019): Gram-scale economical synthesis of trans-coniferyl alcohol and its corresponding thiol. Holzforschung, 74(2): 197-202.
Doi: https://doi.org/10.1515/hf-2018-0297
Prof.(FH) DI Dominik Schild
Professor (FH) Institute Biotechnology
Hon.-Prof.(FH) DI (FH) Rita Seeböck, PhD
Scientific Projekt Staff Institute Biotechnology
Institute Biotechnology
+43 2732 802 574
[email protected]
IMC Campus KremsIMC Campus Trakt D
Molecular Pathology
Molecular Biology
Diagnostics
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Testung von rekombinanten polyklonalen Antikörperfragmenten gegen Gluten-Peptide
Department of Science & Technology
DNA Methylierung im Lungenkrebs und ihre geschlechtsspezifische Auswirkung auf die Effizienz epigenetischer Therapien
Project Leader, Department of Science & Technology
Seeboeck, R., Sarne, V., & Haybaeck, J. (2019): Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels. International journal of molecular sciences, 20(3): 690.
Doi: https://doi.org/10.3390/ijms20030690
Sarne, V., Braunmueller, S., Rakob, L., Seeboeck, R. (2019): The Relevance of Gender in Tumor-Influencing Epigenetic Traits. Epigenomes 2019, 3(1), 6.
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Rita Seeböck and Johannes Haybaeck (2017): Molecular Carcinogenesis of Urinary Bladder Cancer. In Mechanisms of Molecular Carcinogenesis Volume 2 (p.191-206). Cham, Switzerland: Springer.
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017): ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 9(4): 33.
Doi: https://doi.org/10.3390/cancers9040033
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Zopf A, Raim R, Danzer M, Niklas N, Spilka R, Pröll J, Gabriel C, Nechansky A, Roucka M. (2015): Introduction of the hybcell-based compact sequencing technology and comparison to state-of-the-art methodologies for KRAS mutation detection. Biotechniques 58(3):126-34.
Spilka, R., Ernst, C., Bergler, H., Rainer, J., Flechsig, S., Vogetseder, A., Lederer, E., Benesch, M., Brunner, A., Geley, S., Eger, A., Bachmann, F., Doppler, W., Obrist, P., & Haybaeck, J. (2014): eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cellular oncology (Dordrecht), 37(4): 253–267.
Doi: https://doi.org/10.1007/s13402-014-0181-9
Tymoszuk P, Charoentong P, Hackl H, Spilka R, Müller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat JP, Fiegl H, Doppler W (2014): High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer.
Spilka R, Ernst C, Mehta AK, Haybaeck J (2013): Eukaryotic translation initiation factors in cancer development and progression. REVIEW. Cancer Lett 340(1):9-21.
Pilat U, Dechat T, Bertrand AT, Woisetschläger N, Gotic I, Spilka R, Biadasiewicz K, Bonne G, Foisner R (2013): The muscle dystrophy-causing ΔK32 lamin A/C mutant does not impair the functions of the nucleoplasmic lamin-A/C-LAP2α complex in mice. J Cell Sci. 126(Pt 8):1753-62.
Seeböck R, Laimer K, Bachmann F, Spizzo G, Vogetseder A, Wieser M, Müller H, Haybaeck J, Obrist P (2012): Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. J Oncol. 2012:901956.
Haybaeck J, O'Connor T, Seeböck R, Spizzo G, Ensinger Ch, Mikuz G, Brunhuber T, Vogetseder A, Theurl I, Salvenmoser W, Draxl H, Bänziger R, Bachmann F, Schäfer G, Burger M, Obrist P (2010): Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res. 30(4):1047-55..
Gotic I, Schmidt WM, Biadasiewicz K, Leschnik M, Spilka R, Braun J, Stewart CL, Foisner R (2010): Loss of LAP2 alpha delays satellite cell differentiation and affects postnatal fiber-type determination. Stem Cells 28(3):480-8.
Hon.-Prof.(FH) DI (FH) Rita Seeböck, PhD
Scientific Projekt Staff Institute Biotechnology
Prof.(FH) Mag. Dr. Christoph Wiesner
Professor (FH) Institute Biotechnology
Institute Biotechnology
+43 2732 802 276
[email protected]
IMC Campus KremsIMC Campus Trakt G
Cell and Molecular Biology
Drug Screening
Project management
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
EvoFerm
Department of Science & Technology
Spike-Fermentation
Department of Science & Technology
Entwicklung einer optogenetisch kontrollierbaren MSC-Zelllinie für die präzise Regulation immunmodulatorischer Faktoren
Project Leader, Department of Science & Technology
Biomarker-basierte therapeutische Prävention von Knochenmetastasen beim Mammakarzinom: die phathophysiologische Rolle der endostalen Nische
Project Leader, Department of Science & Technology
Entwicklung leistungsfähiger Diagnostikverfahren und neuer Therapieansätze in Inflammation und Sepsis
Project Leader, Department of Science & Technology
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Testung von rekombinanten polyklonalen Antikörperfragmenten gegen Gluten-Peptide
Department of Science & Technology
Zellbasierte Testsysteme für bioaktive Substanzen
Department of Science & Technology
Colleselli, K., Ebeyer-Masotta, M., Neuditschko, B., Stierschneider, A., Pollhammer, C., Potocnjak, M., Hundsberger, H., Herzog, F., Wiesner, C. (2023): Beyond Pattern Recognition: TLR2 Promotes Chemotaxis, Cell Adhesion, and Migration in THP-1 Cells. Cells, 12(10): 1425.
Doi: https://doi.org/10.3390/cells12101425
Stierschneider, A., Neuditschko, B., Colleselli, K., Hundsberger, H., Herzog, F., & Wiesner, C. (2023): Comparative and Temporal Characterization of LPS and Blue-Light-Induced TLR4 Signal Transduction and Gene Expression in Optogenetically Manipulated Endothelial Cells. Cells, 12(697).
Doi: https://doi.org/10.3390/cells12050697
Weitzenböck, HP., Gschwendtner, A., Wiesner, C., Depke, M., Schmidt, F., Trautinger, F., Hengstschläger, M., Hundsberger, H., Mikula, M. (2022): Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment. Cancer Medicine, 11(4): 956-967.
Doi: https://doi.org/10.1002/cam4.4506
Stierschneider, A., Grünstäudl, P., Colleselli, K., Atzler, J., Klein, C., Hundsberger, H., Wiesner, C. (2021): Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line. International Journal of Molecular Sciences, 22(17): 9232.
Doi: https://doi.org/10.3390/ijms22179232
Pretsch, A., Nagl, M., Wiesner, C., Hollaus, R., Genov, M. (2021): Polyguanidine polymers and methods of use thereof (US11013760B2). United States Patent Office.
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Sarne, V., Huter, S., Braunmueller, S., Rakob, L., Jacobi, N., Kitzwögerer, M., Wiesner, C., Obrist, P., & Seeboeck, R. (2020): Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines. International journal of molecular sciences, 21(13): 4595.
Doi: https://doi.org/10.3390/ijms21134595
Pretsch, A., Nagl, M., Wiesner, C., Hollaus, R., Genov, M. (2019): Method for producing polyguanidines (US10335431B2). United States Patent Office.
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Pretsch, A., Nagl, M., Wiesner, C., Burgmann, H. (2017): Bioactive polymers (US9567294B2). United States Patent Office.
Genov, M., Kreiseder, B., Nagl, M., Wiesner, C. et al. (2016): Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB. Journal of Cancer, 7(5): 555.
Doi: https://doi:10.7150/jca.13614
Preisitsch, M., Niedermeyer, T., Heiden, SE., Neidhardt, I., Kumpfmueller, J., Wurster, M., Harmrolfs, K., Wiesner, C., Enke, H., Mueller, R., Mundt, S. (2016): Cylindrofridins A–C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. Journal of natural products, 79(1): 106-115.
Doi: https://doi.org/10.1021/acs.jnatprod.5b00768
Preisitsch, M., Heiden, SE., Beerbaum, M., Niedermeyer, T., Schneefeld, M., Herrmann, J., Kumpfmueller, J., Thuermer, A., Neidhardt, I., Wiesner, C., Daniel, R., Mueller, R., Bange, FC., Schmieder, P., Schweder, T., Mundt, S. (2016): Effects of halide ions on the carbamidocyclophane biosynthesis in Nostoc sp. CAVN2. Marine drugs, 14(1): 21.
Doi: https://doi.org/10.3390/md14010021
Preisitsch, M., Harmrolfs, K., Pham, HT., Heidern, SE., Fuessl, A., Wiesner, C., Pretsch, A., Switecka-Hagenbruch, M., Niedermeyer, TH., Mueller, R., Mundt, S. (2015): Anti-MRSA-acting carbamidocyclophanes H-L from the Vietnamese cyanobacterium Nostoc sp. CAVN2. The Journal of antibiotics, 68(9): 600-600.
Doi: https://doi.org/10.1038/ja.2015.79
Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402
Preisitsch, M., Harmrolfs, K., Pham, H., Heiden, SE., Fuessel, A., Wiesner, C., Pretsch, A., et al. (2015): Anti-MRSA-acting carbamidocyclophanes H–L from the Vietnamese cyanobacterium Nostoc sp. CAVN2. The Journal of antibiotics, 68(3): 165-177.
Doi: https://doi.org/10.1038/ja.2014.118
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929
Kreiseder, B., Orel, L., Bujnow, C., Buschek, S., Pflueger, M., Schuett, W., Hundsberger, H., de Martin, R., Wiesner, C. (2013): α‐Catulin downregulates E‐cadherin and promotes melanoma progression and invasion. International journal of cancer, 132(3): 521-530.
Doi: https://doi.org/10.1002/ijc.27698
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D., Wendel, A., Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in Bioscience, 13: 5374-86.
Doi: https://doi.org/10.2741/3087
Hundsberger, H., Verin, A., Wiesner, C., Pflüger, M., Dulebo, A., Schütt, W., Lasters, I., Männel, D. N., Wendel, A., & Lucas, R. (2008): TNF: a moonlighting protein at the interface between cancer and infection. Frontiers in bioscience : a journal and virtual library, 13: 5374–5386.
Doi: https://doi.org/10.2741/3087
Wiesner, C., Pflueger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schuett, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene interdisziplinar, 3(1).
Wiesner, C., Pflüger, M., Kopecky, J., Stys, D., Entler, B., Lucas, R., Hundsberger, H., Schütt, W. (2008): Implementation of ECIS technology for the characterization of potential therapeutic drugs that promote wound-healing. GMS Krankenhaushygiene Interdisziplinär, 3(1): Doc05.
Wiesner, C., Winsauer, G., Resch, U. et al. (2008): α-Catulin, a Rho signalling component, can regulate NF-κB through binding to IKK-β, and confers resistance to apoptosis. Oncogene , 27: 2159–2169.
Doi: https://doi.org/10.1038/sj.onc.1210863
Wiesner, C., Lucas, R., Pflueger, M., Kleber, C., Kopecky, J., Stys, D., Entler, B., Hundsberger, H., Atzler, J., Hrouzek, P., Lukesova, A., Schuett, W., (2007): Endothelial Cell-Based Methods for the Detection of Cyanobacterial Anti- Inflammatory and Wound-Healing Promoting Metabolites. Drug Metabolism Letters, 1(4): 254-260.
Doi: https://doi.org/10.2174/187231207783221385
Winter, D., Moser, J., Kriehuber, E., Wiesner, C., Knobler, R., Trautinger, F., Bombosi, P., Stingl, G., Petzelbauer, P., Rot, A., & Maurer, D. (2007): Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. Journal of immunology, 179(6): 4272-4282.
Doi: https://doi.org/10.4049/jimmunol.179.6.4272
Lucas, R., Hundsberger, H., Pflueger, M., Fischer, B., Morel, D., Braun, C., Wendel, A., Chakraborty, T., Schuett, W., Wiesner, C., Hamacher, J. (2007): The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug. Letters in Drug Design & Discovery, 4(5): 336-340.
Doi: https://doi.org/10.2174%2F157018007780867816
Hofer-Warbinek, R., Schmid, J.A., Mayer, H., Winsauer, G., Orel, L., Mueller, B., Wiesner, C., Binder, B.R., de Martin, R. (2004): A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell Death & Differentiation, 11(12): 1317 - 1325.
Doi: https://doi.org/10.1038%2Fsj.cdd.4401502
Wiesner, C., Hoeth, M., De Martin, R. (2003): Functional screening for transcription factors (US20030059858A1). United States Patent Office.
Wiesner, C., Hoeth, M., Binder, B.R., de Martin, R. (2002): A functional screening assay for the isolation of transcription factors. Nucleic Acids Research, 30(16): e80.
Doi: https://doi.org/10.1093/nar/gnf079
Prof.(FH) Mag. Dr. Christoph Wiesner
Professor (FH) Institute Biotechnology
Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger
Deputy Head of Institute / Institute Krems Bioanalytics
Institute Krems Bioanalytics
+43 2732 802 369
[email protected]
IMC TFZIMC TFZ Haupthaus (Verwaltungsgebäude 1)
Drug Discovery
Organotypic Disease Models
Bioanalytics and Biomarker
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Stoffwechsel-Plasma-Analyse bei metabolischem Syndrom und Tumorkachexie
Project Leader, Department of Science & Technology
DNA Methylierung im Lungenkrebs und ihre geschlechtsspezifische Auswirkung auf die Effizienz epigenetischer Therapien
Department of Science & Technology
Entwicklung von therapeutischen Peptiden für Krebs- und regenerative Medizin
Project Leader, Department of Science & Technology
Etablierung der molekularen Toxikologie für rasche, frühzeitige sowie sensitive Toxizitätsbestimmungen und Biokompatibilität
Department of Science & Technology
Entwicklung komplexer extrakorporaler Karzinommodelle für die Identifikation personalisierter Krebstherapien
Project Leader, Department of Science & Technology
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Department of Science & Technology
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
Entwicklung neuer Methoden zur Verbesserung von immuntherapeutischen Verfahren in der Onkologie
Project Leader, Department of Science & Technology
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Project Leader, Department of Science & Technology
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Project Leader, Department of Science & Technology
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475
Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017): ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 9(4): 33.
Doi: https://doi.org/10.3390/cancers9040033
Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435
Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7
Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Herzog, J., Rid, R., Wagner, M., Hundsberger, H., Eger, A., Bauer, J., & Önder, K. (2015): Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways. BMC research notes, 8: 785.
Doi: https://doi.org/10.1186/s13104-015-1783-7
Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402
Bakiri, L., Macho-Maschler, S., Custic, I., Niemiec, J., Guío-Carrión, A., Hasenfuss, S. C., Eger, A., Müller, M., Beug, H., & Wagner, E. F. (2015): Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression. Cell death and differentiation, 22(2): 336–350.
Doi: https://doi.org/10.1038/cdd.2014.157
Spilka, R., Ernst, C., Bergler, H., Rainer, J., Flechsig, S., Vogetseder, A., Lederer, E., Benesch, M., Brunner, A., Geley, S., Eger, A., Bachmann, F., Doppler, W., Obrist, P., & Haybaeck, J. (2014): eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cellular oncology (Dordrecht), 37(4): 253–267.
Doi: https://doi.org/10.1007/s13402-014-0181-9
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929
Kapuścik, A., Hrouzek, P., Kuzma, M., Bártová, S., Novák, P., Jokela, J., Pflüger, M., Eger, A., Hundsberger, H., Kopecký, J. (2013): Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem : a European journal of chemical biology, 14(17): 2329-2337.
Doi: https://doi.org/10.1002/cbic.201300246
Rid, R., Herzog, J., Maier, R. H., Hundsberger, H., Eger, A., Hintner, H., Bauer, J. W., Onder, K. (2013): Real-time monitoring of relative peptide-protein interaction strengths in the yeast two-hybrid system. Assay and drug development technologies, 11(4): 269-275.
Doi: https://doi.org/10.1089/adt.2012.496
Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316
Imhof, M., Karas, I., Gomez, I., Eger, A., & Imhof, M. (2013): Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression. Drug discovery today, 18(1-2): 35-42.
Doi: https://doi.org/10.1016/j.drudis.2012.07.010
Maier, C., Maier, R., Rid, R., Trost, A., Hundsberger, H., Eger, A., Hintner, H., Bauer, J., Onder, K. (2012): PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling. BMC molecular biology, 13: 18.
Doi: https://doi.org/10.1186/1471-2199-13-18
Vonach, C., Viola, K., Giessrigl, B., Huttary, N., Raab, I., Kalt, R., Krieger, S., Vo, T. P., Madlener, S., Bauer, S., Marian, B., Hämmerle, M., Kretschy, N., Teichmann, M., Hantusch, B., Stary, S., Unger, C., Seelinger, M., Eger, A., Mader, R., Jäger, W., Schmidt, W., Grusch, M., Dolznig, H., Mikulits, W., Krupitza, G. (2011): NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. British journal of cancer, 105(2): 263-271.
Doi: https://doi.org/10.1038/bjc.2011.194
Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056
Spaderna, S., Schmalhofer, O., Wahlbuhl, M., Dimmler, A., Bauer, K., Sultan, A., Hlubek, F., Jung, A., Strand, D., Eger, A., Kirchner, T., Behrens, J., & Brabletz, T. (2008): The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer research, 68(2): 537–544.
Doi: https://doi.org/10.1158/0008-5472.CAN-07-5682
Mikula M., Lahsnig C., Fischer A. N. M., Proell V., Huber H, Fuchs E., Eger A., Beug H. and Mikulits W. (2007): Epithelial plasticity of hepatocytes during liver tumor progression. Stem cells and their potential for clinical application. NATO Science for Peace and Security. Series/NATO Science Foundation. Springer Netherland, Edition 1.
Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., Sommergruber, W., Schweifer, N., Wernitznig, A., Beug, H., Foisner, R., & Eger, A. (2007): The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene, 26(49): 6979–6988.
Doi: https://doi.org/10.1038/sj.onc.1210508
Aigner, K., Descovich, L., Mikula, M., Sultan, A., Dampier, B., Bonné, S., van Roy, F., Mikulits, W., Schreiber, M., Brabletz, T., Sommergruber, W., Schweifer, N., Wernitznig, A., Beug, H., Foisner, R., & Eger, A. (2007): The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS letters, 581(8): 1617-24.
Doi: https://doi.org/10.1016/j.febslet.2007.03.026
Pacher, M., Seewald, M. J., Mikula, M., Oehler, S., Mogg, M., Vinatzer, U., Eger, A., Schweifer, N., Varecka, R., Sommergruber, W., Mikulits, W., & Schreiber, M. (2007): Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis, 28(1): 49-59.
Doi: https://doi.org/10.1093/carcin/bgl091
Spaderna, S., Schmalhofer, O., Hlubek, F., Berx, G., Eger, A., Merkel, S., Jung, A., Kirchner, T., & Brabletz, T. (2006): A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology, 131(3): 830–840.
Doi: https://doi.org/10.1053/j.gastro.2006.06.016
Stary, M., Pasteiner, W., Summer, A., Hrdina, A., Eger, A., & Weitzer, G. (2005): Parietal endoderm secreted SPARC promotes early cardiomyogenesis in vitro. Experimental cell research, 310(2): 331-43.
Doi: https://doi.org/10.1016/j.yexcr.2005.07.013
Eger, A., Mikulits, W. (2005): Models of Epithelial to Mesenchymal Transition. Drug Discovery Today: Disease Models, 2(1): 57-63.
Doi: https://doi.org/10.1016/j.ddmod.2005.04.001
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005): DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene, 24(14): 2375-85.
Doi: https://doi.org/10.1038/sj.onc.1208429
Eger, A., Stockinger, A., Park, J., Langkopf, E., Mikula, M., Gotzmann, J., Mikulits, W., Beug, H., & Foisner, R. (2004): β-catenin and TGFβ signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene, 23(15): 2672-2680.
Doi: https://doi.org/10.1038/sj.onc.1207416
Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., & Mikulits, W. (2004): Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutation research, 566(1): 9–20.
Doi: https://doi.org/10.1016/s1383-5742(03)00033-4
Stockinger, A., Eger, A., Wolf, J., Beug, H., & Foisner, R. (2001): E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. The Journal of cell biology, 154(6): 1185–1196.
Doi: https://doi.org/10.1083/jcb.200104036
Eger A. and Foisner R. (2000): Dynamic and cross talk of junctional proteins: a molecular basis for the regulation of cell adhesion and epithelial polarity. Protoplasma, 211(3-4): 125-133.
Eger, A., Stockinger, A., Schaffhauser, B., Beug, H., & Foisner, R. (2000): Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. The Journal of cell biology, 148(1): 173-188.
Doi: https://doi.org/10.1083/jcb.148.1.173
Gotzmann, J., Eger, A., Meissner, M., Grimm, R., Gerner, C., Sauermann, G., & Foisner, R. (1997): Two-dimensional electrophoresis reveals a nuclear matrix-associated nucleolin complex of basic isoelectric point. Electrophoresis, 18(14): 2645–2653.
Doi: https://doi.org/10.1002/elps.1150181421
Eger, A., Stockinger, A., Wiche, G., & Foisner, R. (1997): Polarisation-dependent association of plectin with desmoplakin and the lateral submembrane skeleton in MDCK cells. Journal of cell science, 110: 1307-1316.
Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger
Deputy Head of Institute / Institute Krems Bioanalytics
Dipl.-Ing. Dr. Franz Herzog
Endowed Professor / Head Mass Spectrometry / Institute Krems Bioanalytics
Institute Krems Bioanalytics
+43 2732 802 218
[email protected]
IMC TFZIMC TFZ Haupthaus (Verwaltungsgebäude 1)
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Colleselli, K., Ebeyer-Masotta, M., Neuditschko, B., Stierschneider, A., Pollhammer, C., Potocnjak, M., Hundsberger, H., Herzog, F., Wiesner, C. (2023): Beyond Pattern Recognition: TLR2 Promotes Chemotaxis, Cell Adhesion, and Migration in THP-1 Cells. Cells, 12(10): 1425.
Doi: https://doi.org/10.3390/cells12101425
Stierschneider, A., Neuditschko, B., Colleselli, K., Hundsberger, H., Herzog, F., & Wiesner, C. (2023): Comparative and Temporal Characterization of LPS and Blue-Light-Induced TLR4 Signal Transduction and Gene Expression in Optogenetically Manipulated Endothelial Cells. Cells, 12(697).
Doi: https://doi.org/10.3390/cells12050697
Koehnke, T., Liu, X., Haubner, S., Buecklein, V., Haenel, G., Krupka, C., Solis-Mezarino, V., Herzog, F., Subklewe, M. (2022): Integrated multiomic approach for identification of novel immunotherapeutic targets in AML. Biomarker Research, 10(1): 43.
Doi: https://doi.org/10.1186/s40364-022-00390-4
Dipl.-Ing. Dr. Franz Herzog
Endowed Professor / Head Mass Spectrometry / Institute Krems...
Wadih Rassy, MSc
Scientist Institute Biotechnology
Project staff
+43 2732 802 266
[email protected]
IMC Campus KremsIMC Campus Trakt G
Medical and Pharmaceutical Biotechnology
Master of Science in Engineering / full-time
Medical and Pharmaceutical Biotechnology
Bachelor of Science in Engineering / full-time
EvoFerm
Department of Science & Technology
Theraferm
Department of Science & Technology
Nachhaltiges biologisches Recycling von umweltbedenklichen Stoffen (Rare Earth Elements) aus Elektronikabfall und Abwässern
Department of Science & Technology
Synthese und industrielle Verwendung von Hydroxytyrosol
Department of Science & Technology
Rassy, W., Ripper, D., Pomare, E., Winkler, S., Koppensteiner, A., Spadiut O.,Schild, D. (2023): Incorporation of ionic rare earth elements as a form of microbial environmental remediation. Frontiers in Environmental Science, 11(Section Toxicology, Pollution and the Environment).
Doi: https://doi.org/10.3389/fenvs.2023.1112612
Wadih Rassy, MSc
Scientist Institute Biotechnology

Application and admissions – the next steps

You've found a course that's a perfect fit? Great – you’ve already taken the most important step! We’ve put together an overview to guide you through the next steps.

What are the admission requirements for master programmes?

To qualify for a master programme, you must have completed a bachelor degree – with a workload of at least 180 ECTS and lasting at least six semesters – in a related subject, or hold an equivalent degree from a recognised Austrian or foreign higher education institution.

If your undergraduate studies are not sufficiently relevant, for instance if you’ve completed a degree in an unrelated subject, your qualifications will be assessed after we have received your completed application.

Information about accepted previous academic qualifications

Application interview

Everything revolves around the students on our Master degree programmes. That’s why we’d like to get to know you personally.

As part of the online application you will have to write a statement of motivation. Predefined questions about your motivation can be found in the online application. In your answers, which have to be entered in the provided input fields of the online application, you deal with the questions and explain your motivation to study the selected Master degree programme

Your statement of motivation and your CV (curriculum vitae) form the basis for your application interview. The admission interview is a one-to-one interview, usually with the degree programme director.
In addition to getting to know you personally, your motives for the Master degree programme will be discussed, as well as your professional background and the skillset you have acquired so far. Special attention will be paid to your previous academic and professional experience, your methodological and language skills and your general suitability with regard to your intended Master degree programme.

The application interview is held in the language of instruction of the degree programme and can take place online via Microsoft Teams or in presence.

Interview dates

There is usually a selection of dates to choose from, with quotas allocated for each date. You can select a preferred date and time slot for your admission interview during the online application process. In order to still benefit from the full selection of dates, we recommend that you submit your application in good time.

Get an overview of the dates for your programme.

No dates available at the moment.

After you have successfully completed your online application, your application will be checked for completeness and correctness. As soon as this process is completed, we will inform you by e-mail and confirm the date for your admission interview. We will send you the Microsoft Teams Meeting Link in a separate e-mail a few days before the application interview date.

Application for the next study year possible from 01/12/2023

Application deadline for EU nationals	15/05/2024
Application deadline for non-EU nationals	15/04/2024

You've decided for one of our degree programmes? First of all: congratulations and thank you for choosing us! We’ll be happy to guide you step-by-step through your online application.

Details

You would like to plan ahead and would like to know when your degree programme starts? Here you will find the answer!

Details

Questions about the degree programme?

Prospective Student Advisory Service

Do you have questions regarding the entry requirements, the admission procedure and more? Our Prospective Student Advisory Service is happy to help.

+432732802222

[email protected]

Ask a Student

Join our Facebook group: Direct your questions to our students and get first-hand accounts about studying at IMC Krems.

Facebook group

Similar degree programmes

Digital Business Innovation and Transformation

With the Digital Business Innovation and Transformation master degree, you will be qualified to manage digital transformation across multiple industries.

Show details

Medical and Pharmaceutical Biotechnology master degree programme

Looking for an internationally respected master programme that will open up exciting career opportunities in the pharmaceutical industry and research? Potential employers hold our Medical and Pharmaceutical Biotechnology programme in high regard thanks to its broad curriculum.

The degree programme

Developing an interdisciplinary mindset

Focusing on the needs of the industry

International by heart

Excellent career & PhD opportunities

A formula for success: theoretical knowledge + practical experience

1. Advanced courses

2. The electives

3. The research semester and master thesis

Curriculum

Immunology

Hallmarks of Cancer

Molecular Mechanisms of Ageing

Developmental Biology

Bioethics

Equipment and Production Design

Standardization

Legislation for Drugs and Medical Devices

Upstream Processing

Downstream Processing

Recombinant Protein Production - Theory

Recombinant Protein Production - Laboratory

Research Project - Preparation

Process Control and Process Online Monitoring

Drug Discovery Systems

Biostatistics and Trend Analysis

Systems Biology

Structural Bioinformatics and Drug Design

Bioanalytics Laboratory

Personalized Medicine Laboratory

Analytical Methods in Biomedicine

Pharmacokinetics and Pharmacodynamics

GLP and GMP Regulations

Risk Assessment

Quality Management Systems

Project and Portfolio Management

Clinical Studies and GCP

Entrepreneurship in Life Sciences

Fermentation of Complex Host Systems

Scale Up - Scale Down Techniques

Fermentation Technology - Laboratory I

Advanced Therapeutic Development Laboratory I

Pathophysiology and Molecular Therapies

Equipment Test and Process Validation

Fermentation Technology - Laboratory II

Stem Cells, Gene Therapy and Regenerative Medicine

Immunology Based Therapies

Advanced Therapeutic Development Laboratory II

Master Thesis - Part I

Master Thesis - Coaching Seminar I

Research Project

Current Issues in Bioprocess Engineering

Current Issues in Advanced Therapeutic Development

Master Thesis - Part II

Master Thesis - Coaching Seminar II

Master Exam

Electives

Bioprocess Engineering

Advanced Therapeutics Development

Newsletter & additional information

Newsletter & brochures

Career paths

Opinions: Medical and Pharmaceutical Biotechnology

Our team

Prof.(FH) Priv.-Doz. Mag. Dr. Harald Hundsberger

Head of Institute Biotechnology / Programme Director Medical and Pharmaceutical Biotechnology

Core Competencies

DI (FH) Anita Koppensteiner

Hon.Prof.(FH) Mag. Alfred Siedl

Prof.(FH) Dr. Barbara Entler

Prof.(FH) DI Bernhard Klausgraber

Prof.(FH) Dr. Christian Klein

Prof.(FH) Priv.Doz. Dr. Reinhard Klein

Prof.(FH) Mag. Dana Mezricky

Prof.(FH) DI Dominik Schild

Hon.-Prof.(FH) DI (FH) Rita Seeböck, PhD

Prof.(FH) Mag. Dr. Christoph Wiesner

Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger